[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 297
1. Pipp I, Wagner L, Rössler K, Budka H, Preusser M: Secretagogin expression in tumours of the human brain and its coverings. APMIS; 2007 Apr;115(4):319-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found focal or widespread secretagogin expression in tumour cells in 1/18 oligoastrocytomas, 1/19 oligodendrogliomas, 2/20 anaplastic oligodendrogliomas, 2/9 ependymomas, 2/11 anaplastic ependymomas, 2/10 glioblastomas, 3/11 gangliogliomas and 1/2 anaplastic gangliogliomas, 10/10 central neurocytomas, 5/10 classic medulloblastomas, 4/5 desmoplastic medulloblastomas, 3/5 large cell/anaplastic medulloblastomas, 3/5 neuroblastomas, 3/10 meningiomas, 2/10 haemangioblastomas, and 13/19 pituitary adenomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Calcium-Binding Proteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504298.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / SCGN protein, human; 0 / Secretagogins
  •  go-up   go-down


2. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus; 2006;20(4):E1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rising trends were noticed for glioblastoma multiforme (GBM), oligodendroglioma, anaplastic astrocytoma, medulloblastoma, and mixed glioma, and falling trends were observed for astrocytoma not otherwise specified and malignant glioma.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Glioma / epidemiology. Medulloblastoma / epidemiology. Oligodendroglioma / epidemiology. Population Surveillance

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709014.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Smith SF, Simpson JM, Sekhon LH: What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades? J Clin Neurosci; 2005 Nov;12(8):915-20; discussion 921
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades?
  • OBJECTIVE: To determine changes since 1977 in demographic characteristics, tumour frequencies, surgical management, morbidity and survival for 1,339 patients discharged with astrocytoma (A) and oligodendroglioma (O), which comprise the majority of primary brain cancers, recorded prospectively in northern Sydney neurosurgery databases.
  • Of 144 re-biopsies, 16% had less anaplastic pathology, 54% the same and 30% more anaplastic pathology than the first biopsy.
  • Age and histopathologic grade were predictors of survival from 1980.
  • Sex and era of diagnosis did not influence survival.
  • After adjustment for age using proportional hazards regression, survival improved only for anaplastic A, with a 60% improvement for patients diagnosed in era 3, and a 50% improvement for patients diagnosed in era 4 relative to those in era 1.
  • CONCLUSIONS: Although markers of inpatient care have improved since the 1980s, age-adjusted survival has not increased except for patients with anaplastic A.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neurosurgical Procedures / statistics & numerical data. Oligodendroglioma / surgery. Postoperative Complications

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326271.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


Advertisement
4. Fuller GN, Mircean C, Tabus I, Taylor E, Sawaya R, Bruner JM, Shmulevich I, Zhang W: Molecular voting for glioma classification reflecting heterogeneity in the continuum of cancer progression. Oncol Rep; 2005 Sep;14(3):651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas, the most common brain tumors, are generally categorized into two lineages (astrocytic and oligodendrocytic) and further classified as low-grade (astrocytoma and oligodendroglioma), mid-grade (anaplastic astrocytoma and anaplastic oligodendroglioma), and high-grade (glioblastoma multiforme) based on morphological features.
  • Thus, the actual voting results, which are typically used only to decide the winning class label in k-nearest neighbor algorithms, provide a useful method for gaining deeper insight into the stage of a tumor in the continuum of cancer development.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077969.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  •  go-up   go-down


5. Uzuka T, Takahashi H, Tanaka R: Interstitial hyperthermia with intra-arterial injection of adriamycin for malignant glioma. Neurol Med Chir (Tokyo); 2006 Jan;46(1):19-23; discussion 23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial hyperthermia with intra-arterial injection of adriamycin for malignant glioma.
  • A new method for treating malignant glioma by concurrent intra-arterial injection of adriamycin during thermotherapy was performed in seven patients with malignant glioma, four males and three females, with five cases of glioblastoma and two of anaplastic oligodendroglioma.
  • Intra-arterial injection chemotherapy during hyperthermia is a promising therapeutic method for treatment of malignant glioma with few adverse effects.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434821.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


6. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, Ylstra B, Leenstra S: The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene; 2008 Mar 27;27(14):2091-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids.
  • We obtained genomic profiles by array comparative genomic hybridization of both short- and long-term primary cell and spheroid cultures, derived from seven glioblastomas and one anaplastic oligodendroglioma.
  • It is concluded that genomic profiles of primary cell cultures from glioblastoma are frequently deviant from parental tumor profiles, whereas spheroids are genetically more representative of the glioblastoma.
  • [MeSH-minor] Cell Culture Techniques. Genomics. Humans. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934519.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Miwa K, Shinoda J, Yano H, Iwama T: Relatively decreased 11C-methionine uptake within the anaplastic component of a mixed-grade oligodendroglioma. AJNR Am J Neuroradiol; 2007 Nov-Dec;28(10):2005-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relatively decreased 11C-methionine uptake within the anaplastic component of a mixed-grade oligodendroglioma.
  • A 56-year-old woman presented with a mixed-grade oligodendroglioma.
  • The part of the lesion with higher MET uptake was identified as an ordinary oligodendroglioma, whereas the part of the lesion with lower MET uptake was an anaplastic component of oligodendroglioma.
  • With oligodendrogliomas, we should be aware of the possibility that MET uptake decreases paradoxically with an increased anaplastic component of oligodendroglioma cells.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Frontal Lobe. Oligodendroglioma / radionuclide imaging. Positron-Emission Tomography


8. Kim L, Glantz M: Chemotherapeutic options for primary brain tumors. Curr Treat Options Oncol; 2006 Nov;7(6):467-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most common primary brain tumors.
  • Surgery and radiation remain the primary modalities of therapy for malignant brain tumors.
  • The role of chemotherapy in malignant gliomas, especially glioblastoma multiforme, has been inconclusive.
  • In addition to this encouraging progress, recent experience has shown that selected malignant brain tumors--for example, anaplastic oligodendrogliomas, primary central nervous system lymphomas, medulloblastomas, and intracranial germ cell tumors--are often highly responsive to chemotherapy.
  • Molecular genetic studies are becoming indispensable aids in the diagnosis and treatment of the malignant gliomas.
  • For example, we have learned that allelic loss of chromosome 1p is a significant predictor of chemosensitivity, whereas combined loss of chromosomes 1p and 19q is a strong predictor of chemosensitivity, progression-free survival, and overall survival in patients with anaplastic oligodendroglioma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1987 Jul;56(1):89-90 [3620320.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]
  • [Cites] Oncology (Williston Park). 1995 Jan;9(1):63-71; discussion 71, 75-6, 78 [7718442.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):127-37 [11325440.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Arch Neurol. 2005 Oct;62(10):1595-600 [16216945.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Trends Genet. 1995 Oct;11(10):412-5 [7482768.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1561-7 [9552066.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):299-305 [16645720.001]
  • [Cites] Radiother Oncol. 2002 Sep;64(3):259-73 [12242114.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1141-5 [16603598.001]
  • [Cites] Ann Neurol. 1990 May;27(5):573-4 [2360797.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 1988 May 1;61(9):1862-6 [3355979.001]
  • [Cites] Acta Neuropathol. 1984;64(4):265-72 [6391068.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1246-52 [16525179.001]
  • [Cites] Neurology. 1994 Sep;44(9):1721-7 [7936304.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Anticancer Res. 1991 Mar-Apr;11(2):719-27 [2064325.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • (PMID = 17032559.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


9. Gilbert MR, Lang FF: Anaplastic oligodendroglial tumors: a tale of two trials. J Clin Oncol; 2006 Jun 20;24(18):2689-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglial tumors: a tale of two trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Humans. Lomustine / therapeutic use. Loss of Heterozygosity. Procarbazine / therapeutic use. Randomized Controlled Trials as Topic. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [CommentOn] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • (PMID = 16782906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


10. Han SR, Yoon SW, Yee GT, Choi CY, Lee DJ, Sohn MJ, Chang SH, Whang CJ: Extraneural metastases of anaplastic oligodendroglioma. J Clin Neurosci; 2008 Aug;15(8):946-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases of anaplastic oligodendroglioma.
  • Extraneural metastases from primary central nervous system (CNS) tumors are unusual, and glioblastomas and medulloblastomas constitute the majority of these.
  • That oligodendroglioma frequently seeds within the CNS is well known.
  • However, extraneural metastases of anaplastic oligodendroglioma are rare.
  • We report a 50-year-old woman who developed multiple lung and liver metastases 28 months after resection of a temporal lobe anaplastic oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Oligodendroglioma / pathology


11. Poulsen HS: [Gliomas in adults: primary non-surgical treatment]. Ugeskr Laeger; 2006 Nov 20;168(47):4082-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy has a definite place in the treatment of low-grade gliomas, but the timing is a matter of dispute.
  • Anaplastic astrocytomas should be treated with postoperative radiation therapy with or without adjuvant chemotherapy.
  • Anaplastic oligodendroglioma should be treated with radiation therapy only.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Chemotherapy, Adjuvant. Ependymoma / drug therapy. Ependymoma / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy. Radiotherapy Dosage. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134603.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 10
  •  go-up   go-down


12. Iwamoto FM, Reiner AS, Nayak L, Panageas KS, Elkin EB, Abrey LE: Prognosis and patterns of care in elderly patients with glioma. Cancer; 2009 Dec 1;115(23):5534-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The current study was conducted to evaluate the patterns of care and survival of older adults with oligodendroglioma (OLI) and astrocytoma (AST) from a large population-based registry.
  • Patients with a diagnosis of glioblastoma were excluded.
  • The impact of demographic characteristics and comorbidities on the probability of undergoing surgical resection, radiotherapy (RT), and chemotherapy within 6 months of diagnosis was assessed using multivariate logistic regression.
  • RESULTS: A total of 1067 patients (891 with AST and 176 with OLI) were included; the median survival was 9 months for patients with low-grade AST, 4 months for patients with anaplastic AST, 57 months for patients with low-grade OLI, and 9 months for patients with anaplastic OLI.
  • Approximately 54% of patients underwent resection at the time of diagnosis; 66% received RT, and 13% received chemotherapy within 6 months of diagnosis.
  • In a multivariate regression analysis, age and tumor grade were found to be the most significant predictors of resection, RT, or chemotherapy.
  • Patients with anaplastic tumors were treated with resection, RT, and chemotherapy more often than patients with low-grade tumors, and OLI patients received chemotherapy more frequently than AST.
  • CONCLUSIONS: Data from the current study suggested that histologic diagnosis and tumor grade retained significant prognostic value in this elderly AST and OLI population.
  • Furthermore, age and tumor grade were found to influence the probability of undergoing surgery, RT, and chemotherapy in this cohort.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19708033.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Miller CR, Dunham CP, Scheithauer BW, Perry A: Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol; 2006 Dec 1;24(34):5419-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
  • PURPOSE: High-grade gliomas (HGGs; WHO grades 3-4) are highly diverse, with survival times ranging from months to years.
  • WHO 2000 grading criteria for high-grade oligodendroglial neoplasms [anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO)] remain subjective, and the existence of grade 4 variants is controversial.
  • PATIENTS AND METHODS: Overall survival (OS) of 1,093 adult patients with a cerebral HGG newly diagnosed between 1990 and 2005 was analyzed by univariate and multivariate models for significance of the following factors: patient age, surgery type, year of diagnosis, endothelial proliferation, necrosis, oligodendroglial histology, treatment center, and chromosome 1p, 19q, 7p (EGFR), and 10q (PTEN) abnormalities by fluorescence in situ hybridization (FISH).
  • In addition to patient age, the following were significant independent prognostic factors (P .001): grade and surgery type for the entire HGG cohort; modified grade for AOA (3 v 4); and modified grade, 1p/19q codeletion status, and oligodendroglial histology for the 586 HGGs analyzed by FISH.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32CA009547
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


14. Soichi O, Masanori N, Hideo T, Kazunori A, Nobuya I, Jun-ichi K: Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. Neurosurgery; 2007 Apr;60(4):707-14; discussion 714
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas.
  • METHODS: To determine whether or not ABCA2 can distinguish oligodendrogliomas from astrocytic tumors, the authors investigated the expression of ABCA2 in a panel of 55 glioma tissues (13 oligodendrogliomas, nine anaplastic oligodendrogliomas, 12 anaplastic astrocytomas, and 21 glioblastomas) using real-time reverse-transcriptase polymerase chain reaction analysis, immunoblot analysis, and immunohistochemistry analysis.
  • The authors also compared the expression of Olig2, a recently identified marker for oligodendroglioma.
  • RESULTS: The relative expression level of ABCA2 messenger ribonucleic acid determined by real-time quantitative polymerase chain reaction is significantly higher (by a factor of five) in oligodendroglioma than in anaplastic astrocytoma or glioblastoma.
  • It was moderately increased in anaplastic oligodendrogliomas.
  • In immunohistochemical analysis, ABCA2 exhibited remarkable immunopositivity in 11 out of 13 oligodendrogliomas showing a granular pattern in the cytoplasm of tumor cells.
  • However, ABCA2 was completely negative in most anaplastic astrocytomas (75%) and glioblastomas (76%).
  • Anaplastic oligodendroglioma showed an intermediate pattern: strongly positive in two out of nine samples and negative in seven out of nine samples.
  • However, Olig2 was strongly positive in most anaplastic astrocytomas (83%) and glioblastomas (71%).
  • Although there was no difference in the detection of oligodendroglial tumors, the specificity (negative in astrocytic tumor) was significantly higher in ABCA2 than in Olig2.
  • CONCLUSION: These lines of evidence suggest that ABCA2 could be a molecular marker for oligodendroglioma.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Neoplasm Proteins / metabolism. Oligodendroglioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415208.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCA2 protein, human; 0 / ATP-Binding Cassette Transporters; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


15. Zhou YH, Hess KR, Raj VR, Yu L, Liu L, Yung AW, Linskey ME: Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomark Insights; 2010 Dec 22;5:153-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables.
  • In this study, multivariate Cox proportional hazards analyses were done based on overall survival (OS) of 100 glioblastoma multiformes (GBMs, 92 events), 49 anaplastic astrocytomas (AAs, 33 events), 45 gliomas with oligodendroglial features, including anaplastic oligodendroglioma (AO, 13 events) and oligodendraglioma (O, 9 events).
  • RESULTS: Age is positively associated with overall grade (4 for GBM, 3 for AA, 2_1 for AO_O), but lacks significant prognostic value in each grade.
  • Univariate models revealed opposing prognostic effects of ABCG2, MELK, BMI1, PROM1, IGFBP2, PAX6, RPS9, and MSI1 expressions for astrocytic (GBM and AA) and oligodendroglial tumors (AO_O).


16. Noshita N, Mashiyama S, Fukawa O, Asano S, Watanabe M, Tominaga T: Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity--case report. Neurol Med Chir (Tokyo); 2010;50(2):161-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracranial metastasis of anaplastic oligodendroglioma with 1p19q loss of heterozygosity--case report.
  • We report a rare case of anaplastic oligodendroglioma with extracranial metastasis, showing 1p19q co-deletion in both the brain tissue and the metastatic site.
  • A 53-year-old man first presented with a left frontal tumor.
  • The tumor was subtotally removed and irradiation was performed for the residual tumor and tumor bed.
  • Histological examination revealed anaplastic oligodendroglioma, proved to be the same as the previous brain tumor.
  • We confirmed 1p19q loss of heterozygosity in both lesions, suggesting that 1p19q co-deletion might important to extracranial metastasis of oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / secondary. Oligodendroglioma / genetics. Oligodendroglioma / secondary
  • [MeSH-minor] Cervical Vertebrae / pathology. Chromosomes, Human, Pair 1 / genetics. DNA Mutational Analysis. Fatal Outcome. Frontal Lobe / pathology. Genetic Predisposition to Disease / genetics. Genotype. Humans. Loss of Heterozygosity / genetics. Lymph Nodes / pathology. Male. Middle Aged. Neck / pathology. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Spinal Canal / pathology. Thoracic Wall / pathology. Thymus Gland / pathology


17. Fiorentini G, Giovanis P, Rossi S, Dentico P, Paola R, Turrisi G, Bernardeschi P: A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia. In Vivo; 2006 Nov-Dec;20(6A):721-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia.
  • The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients.
  • Twelve patients with histologically diagnosed malignant glioma entered the study.
  • Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma.
  • ET appears to have some effectiveness in adults with relapsed malignant glioma.
  • [MeSH-major] Brain Neoplasms / therapy. Electric Stimulation Therapy. Glioma / therapy. Hyperthermia, Induced. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203754.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


18. Perry J, Chambers A, Spithoff K, Laperriere N: Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol; 2007 Oct;14(5):189-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliadel wafers in the treatment of malignant glioma: a systematic review.
  • QUESTION: What is the safety and efficacy of interstitial chemotherapy with carmustine-loaded polymers (Gliadel wafers: MGI Pharma, Bloomington, MN, U.S.A.) in the treatment of newly diagnosed or recurrent malignant glioma (that is, glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligoastrocytoma, and anaplastic oligodendroglioma)?
  • PERSPECTIVES: Malignant glioma is the most common type of primary brain tumour in adults.
  • RESULTS: Two RCTS that compared Gliadel to placebo in patients with newly diagnosed malignant glioma were obtained.
  • Both RCTS reported a significant survival benefit for patients who received Gliadel as compared with patients in the control group.
  • One RCT and one prospective cohort study were obtained that examined the role of Gliadel in patients with recurrent malignant glioma.
  • CONCLUSIONS: Gliadel is an option for selected patients with newly diagnosed malignant glioma where a near gross total resection is possible.
  • Gliadel is also an option for patients with surgically resectable recurrent malignant glioma.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3 [10414561.001]
  • [Cites] Surg Neurol. 2000 May;53(5):458-64 [10874145.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • (PMID = 17938702.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2002480
  • [Keywords] NOTNLM ; Gliadel / carmustine / glioblastoma / interstitial chemotherapy / malignant glioma / systematic review
  •  go-up   go-down


19. Dunbar EM: The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors. Curr Treat Options Oncol; 2009 Aug;10(3-4):216-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors.
  • Pure and mixed anaplastic oligodendrogliomas (AO/mixed-AOs) remain terminal primary brain tumors, without a defined optimal initial therapy, and without sufficiently active and tolerable therapies at recurrence/progression (R/P).
  • Partly secondary to biases regarding the relative toxicities of tumor burden vs. treatment effect, therapy remains highly individualized.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2008 Aug;89(1):37-45 [18458822.001]
  • [Cites] J Neurol. 2002 Aug;249(8):1055-7 [12195453.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1759-65 [16541434.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4659-65 [18824712.001]
  • [Cites] J Neurooncol. 2007 May;83(1):53-60 [17245623.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3427-32 [9396393.001]
  • [Cites] Neurology. 2003 Jan 14;60(1):151 [12525747.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1637-8 [17470853.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Neurooncol. 2009 Mar;92 (1):57-63 [19011763.001]
  • [Cites] Curr Treat Options Neurol. 2008 Jul;10(4):295-307 [18579016.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):231-8 [18480965.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):807-13 [14770438.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5723-30 [18089866.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1727-31 [14630676.001]
  • [Cites] Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44 [7407756.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] J Neurooncol. 1997 Feb;31(3):273-8 [9049856.001]
  • [Cites] Ann Neurol. 1990 May;27(5):573-4 [2360797.001]
  • [Cites] J Neurooncol. 2009 Jan;91(2):183-9 [18850068.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):262-72 [18272388.001]
  • [Cites] Neuro Oncol. 2009 Apr;11(2):167-75 [18779504.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Curr Oncol. 2007 Oct;14(5):189-94 [17938702.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2061-2; author reply 2062 [18421064.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2473-6 [16270316.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):187-93 [18458821.001]
  • (PMID = 19381820.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Number-of-references] 44
  •  go-up   go-down


20. Gil-Salú JL, Nieto A, Rodríguez-Gutiérrez JF, Almarcha J: [Allelic loss at 1p/19q analysis in brain tumors of glial lineage]. Neurocirugia (Astur); 2007 Aug;18(4):285-93; discussion 293
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Were included in the first part of this study 45 sample of neuroepithelial tissue supratentorial tumors: 29 glioblastoma, 1 gliosarcoma, 7 diffuse astrocytoma grade II, 1 oligoastrocytoma, 3 oligodendroglioma, 1 anaplastic oligodendroglioma, 1 xanthoastrocytoma, 1 dysembryoplastic neuroepithelial tumour and 1 pilocytic astrocytoma.
  • 80% of oligodendroglial tumors, 14% glioblastoma and 14% of diffuse astrocytoma grade II.
  • [MeSH-minor] Base Sequence. DNA, Neoplasm / analysis. Genetic Markers. Humans. Microsatellite Repeats. Molecular Sequence Data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882335.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


21. Yokoo H, Tanaka Y, Nobusawa S, Nakazato Y, Ohgaki H: [Analysis of S100beta-v-erbB transgenic rats prone to brain tumors]. Brain Nerve; 2009 Jul;61(7):765-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, they were classified into four subtypes: glioblastoma-like malignant glioma, anaplastic oligodendroglioma, low-grade oligodendroglioma, and low-grade astrocytoma.
  • Eleven transgenic rats developed two different histological types of brain tumor, which were considered to be of multiclonal origin, because of the lack of mutual histological transitions.
  • Diffuse immunoreactivity for Olig2 and Nkx2.2 was observed in neoplastic cells in all oligodendroglial tumors, but not in the malignant gliomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genetic Predisposition to Disease / genetics. Glioblastoma / genetics. Nerve Growth Factors / genetics. Oligodendroglioma / genetics. Oncogene Proteins v-erbB / genetics. Rats, Transgenic / genetics. S100 Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618853.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nerve Growth Factors; 0 / Oncogene Proteins v-erbB; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 22
  •  go-up   go-down


22. Liu JG, Liu YH, Cai J, Liu XS, Song WZ, Huang Y, Mao Q: [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):868-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using immunohistochemistry to detect the expression of EGFR and PTEN and adopting confocal technology to verify their location in the specimens of 25 respectively glioblastoma multiformes, medulloblastomas, anaplastic oligodendrogliomas, and anaplastic ependymomas.
  • They were 36% and 8% in medulloblastomas, and 28% and 8% in anaplastic oligodendrogliomas, and 24% and 4% in anaplastic ependymomas.
  • PTEN mutation and EGFR overexpression are rare in medulloblastoma, anaplastic oligodendroglioma, and anaplastic ependymoma, so the EGFR or PTEN targeted antitumor approaches may be useful in glioblastoma multiformes but the other 3 tumors.


23. Abrey LE: Anaplastic oligodendroglioma. Curr Neurol Neurosci Rep; 2007 May;7(3):189-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [CommentOn] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2689-90 [16782906.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 17488583.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ide T, Miyoshi N, Ochiai K, Yasuda N: Oligoastrocytoma of the brain in a hooded crane (Grus monacha). Vet Pathol; 2009 Mar;46(2):309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cerebral tumor was identified at necropsy in a mature female hooded crane (Grus monacha).
  • On gross examination, the cut surface of the tumor revealed a soft gelatinous mass.
  • On histologic examination, the tumor was mainly composed of 2 discrete components that resembled oligodendroglioma and astrocytoma.
  • Both components had anaplastic changes, such as pleomorphism, high proliferative activity, microvascular proliferation, and necrosis.
  • Based on these findings, the tumor was diagnosed as an oligoastrocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261644.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hilbig A, Barbosa-Coutinho LM, Netto GC, Bleil CB, Toscani NV: [Immunohistochemistry in oligodendrogliomas]. Arq Neuropsiquiatr; 2006 Mar;64(1):67-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemistry in oligodendrogliomas].
  • [Transliterated title] Imunoistoquímica em oligodendrogliomas.
  • Oligodendrogliomas (OL) are neuroepithelial tumors characterized by the presence of uniformly round nuclei with a clear cytoplasm around it.
  • Immunohistochemistry with glial and neuronal markers may be helpful in differential diagnosis.
  • Ten cases showed anaplastic characteristics.
  • The widespread staining with neuronal marker suggests central neurocytoma, but this diagnosis should not be done with small amount of tissue.
  • [MeSH-major] Antibodies, Neoplasm / analysis. Brain Neoplasms / pathology. Neuroglia / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Humans. Immunohistochemistry. Male. Middle Aged. S100 Proteins / analysis. S100 Proteins / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622556.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


26. Schittenhelm J, Erdmann T, Maennlin S, Will BE, Beschorner R, Bornemann A, Meyermann R, Mittelbronn M: Gliosarcoma with chondroid and osseous differentiation. Neuropathology; 2007 Feb;27(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroradiological examinations revealed a large left temporo-occipital cystic and calcified tumor mass measuring 6 cm in diameter, which was suspicious for an oligodendroglioma or a choroid plexus carcinoma.
  • The tumor demonstrated a biphasic pattern consisting of focal anaplastic glial components with vascular proliferation and necrosis.
  • Accounting for only approximately 2% of glioblastomas, gliosarcomas represent a rare entity of intrinsic CNS neoplasms.
  • Interestingly, in our case, the tumor exhibited features of both cartilaginous and osseous differentiation and multifocally showed a sharp transformation zone between highly malignant gliosarcomatous tumor areas and well-differentiated non-proliferative metaplastic regions.

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319288.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


27. Stark AM, Hugo HH, Mehdorn HM, Knerlich-Lukoschus F: Acute Hydrocephalus due to Secondary Leptomeningeal Dissemination of an Anaplastic Oligodendroglioma. Case Rep Med; 2009;2009:370901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute Hydrocephalus due to Secondary Leptomeningeal Dissemination of an Anaplastic Oligodendroglioma.
  • Secondary leptomeningeal dissemination of oligodendroglioma is very rare.
  • We report the case of a 38-year-old Caucasian male who presented with acute hydrocephalus.
  • 8 months before, the patient had undergone craniotomy for right frontal anaplastic oligodendroglioma, WHO grade III.
  • By that time, there was no evidence of tumor dissemination.
  • MRI now ruled out local tumor progression but revealed meningeal contrast enhancement along the medulla, the myelon, and the cauda equina.
  • Malignant cells were not detectable.
  • Surgical treatment consisted in (1) placement of an ommaya reservoir for daily CSF puncture, (2) Spinal dural biopsy confirming leptomeningeal oligodendroglioma metastasis, and (3) ventriculo-peritoneal shunt placement after CSF protein has decreased to 1500-2000 mg/l.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1122-6 [10871026.001]
  • [Cites] Neuropediatrics. 2002 Oct;33(5):266-70 [12536370.001]
  • [Cites] J Neuropathol Exp Neurol. 1951 Jan;10(1):16-29 [14804124.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):75-9 [17077938.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):166-8; discussion 169 [7708153.001]
  • [Cites] Acta Neurochir (Wien). 1977;37(1-2):125-37 [878921.001]
  • [Cites] Br J Neurosurg. 1995;9(5):639-44 [8561936.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):724-8 [7674024.001]
  • (PMID = 20052406.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2797365
  •  go-up   go-down


28. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO: YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res; 2005 Mar 15;11(6):2258-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
  • PURPOSE AND EXPERIMENTAL DESIGN: In modern neuro-oncology, no variable affects therapeutic decisions and prognostic estimation more than tumor classification.
  • We showed recently that class prediction models, based on gene expression profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than standard pathology.
  • In the present study, we used immunohistochemistry to investigate YKL-40 protein expression in independent sets of glioblastomas and anaplastic oligodendrogliomas to determine whether this single marker can aid classification of these high-grade gliomas.
  • RESULTS AND CONCLUSIONS: Glioblastomas show strikingly more YKL-40 expression than anaplastic oligodendrogliomas.
  • Only 2 of 37 glioblastomas showed completely negative YKL-40 staining in both tumor cells and extracellular matrix, whereas 18 of 29 anaplastic oligodendrogliomas were completely negative in non-microgemistocytic tumor cells and extracellular matrix.
  • Tumor cell staining intensity was also markedly different: 84% of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76% of anaplastic oligodendrogliomas either did not stain or stained at only 1+.
  • YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas.
  • Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Glioblastoma / diagnosis. Glioblastoma / metabolism. Glycoproteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adipokines. Autoantigens / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Diagnosis, Differential. Glial Fibrillary Acidic Protein / analysis. Humans. Immunoenzyme Techniques. Lectins. Neoplasm Staging. Prognosis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788675.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 57683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Glycoproteins; 0 / Lectins
  •  go-up   go-down


29. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res; 2005 Jan 1;11(1):267-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
  • PURPOSE: The activator protein (AP)-2alpha transcription factor plays a crucial role in the progression of several human tumors, including malignant melanoma, prostate, and breast cancer.
  • Anderson Cancer Center since 1986 to include 72 glioblastomas, 49 anaplastic astrocytomas, 9 low-grade astrocytoma, 37 oligodendrogliomas, 37 anaplastic oligodendrogliomas, 15 mixed oligoastrocytomas, 20 anaplastic mixed oligoastrocytomas, and 7 gliosarcomas.
  • RESULTS: AP-2alpha expression was lost on 99% (P < 0.001) and 98% (P < 0.001) of glioblastomas and anaplastic astrocytomas, respectively, compared with grade 2 astrocytomas and normal brain, all of which (100%) maintained expression of AP-2alpha.
  • However, there was no significant effect of loss of AP-2alpha expression on survival observed after adjustment for patient age, Karnofsky Performance Scale score, tumor grade, and extent of resection (rate ratio, 1.2; 95% confidence interval, 0.6-2.2; P = 0.6).
  • CONCLUSIONS: AP-2alpha expression correlates inversely with glioma grade, suggesting a direct role in glioma tumorigenicity, possibly through subsequent deregulation of target genes.
  • Of all the previously characterized markers of progression, the loss of AP-2alpha would be the most common (96.2%) molecular marker as an astrocytic tumor evolves from grade 2 to 3.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amino Acid Motifs. Antigens, CD / biosynthesis. Antigens, CD146. Astrocytoma / metabolism. Brain / metabolism. Cell Cycle Proteins / biosynthesis. Cell Line, Tumor. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p21. Disease Progression. Humans. Immunohistochemistry. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Neural Cell Adhesion Molecules / biosynthesis. Oligodendroglioma / metabolism. Oligonucleotide Array Sequence Analysis. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins c-kit / biosynthesis. Time Factors. Transcription Factor AP-2. Treatment Outcome. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671555.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / PHS HHS / / T-32-09666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / MCAM protein, human; 0 / Neural Cell Adhesion Molecules; 0 / TFAP2A protein, human; 0 / Transcription Factor AP-2; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


30. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res; 2010 Mar 1;16(5):1597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
  • We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma.
  • CONCLUSION: In this homogeneously treated group of anaplastic oligodendroglioma patients, the presence of IDH1 mutations was found to carry a very strong prognostic significance for OS but without evidence of a predictive significance for outcome to PCV chemotherapy.
  • [MeSH-major] Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Female. Genes, erbB-1. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Lomustine / therapeutic use. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Procarbazine / therapeutic use. Prognosis. Promoter Regions, Genetic. Radiotherapy. Treatment Outcome. Tumor Suppressor Proteins / genetics. Vincristine / therapeutic use. Young Adult


31. Quant EC, Drappatz J, Wen PY, Norden AD: Recurrent high-grade glioma. Curr Treat Options Neurol; 2010 Jul;12(4):321-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent high-grade glioma.
  • OPINION STATEMENT: Opinions vary on the best treatment options for recurrent high-grade glioma.
  • Age, performance status, histology, tumor size and location, O6-methylguanine-DNA methyltransferase (MGMT) methylation status for glioblastoma, 1p/19q status for oligodendroglial tumors, and the number and types of prior therapies are important considerations.
  • Enrollment in a clinical trial is the optimal choice for most patients with recurrent high-grade glioma after failure of radiation therapy and temozolomide.
  • For patients who are ineligible or do not have access to clinical trials, then either bevacizumab monotherapy or bevacizumab in combination with a second agent such as irinotecan is recommended.
  • Involved-field external beam radiation should be considered for patients with anaplastic gliomas who have not received radiation.
  • For patients with anaplastic astrocytoma who progress after radiotherapy, temozolomide may be used.
  • For patients with anaplastic oligodendroglioma who progress after radiotherapy, PCV chemotherapy and temozolomide are options.
  • Oligodendroglial tumors with 1p/19q deletions are more likely to respond to treatment.
  • In the past, carmustine was commonly used to treat recurrent high-grade glioma, but the utility of carmustine in the modern era is unknown because most studies were performed prior to the widespread use of temozolomide.
  • High-precision re-irradiation such as stereotactic radiosurgery is another option in high-grade glioma, especially for patients with poor bone marrow reserve or inability to tolerate chemotherapy, but there is a paucity of studies with adequate controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 10;23 (23 ):5294-304 [15998902.001]
  • [Cites] Neuro Oncol. 2009 Oct;11(5):550-5 [19332770.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Surg Neurol. 2008 May;69(5):506-9; discussion 509 [18262245.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] BMC Cancer. 2007 Aug 30;7:167 [17760992.001]
  • [Cites] J Neurooncol. 1993 Aug;17(2):167-73 [8145061.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2905-8 [19451418.001]
  • [Cites] Ther Clin Risk Manag. 2007 Oct;3(5):707-15 [18472995.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1268-74 [19204207.001]
  • [Cites] Mol Cells. 2009 Jul 31;28(1):7-12 [19655094.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):81-3 [16944309.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1963-72 [20231676.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55 [19543728.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Nov;5(11):634-44 [18711427.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14 (21):7068-73 [18981004.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1350-60 [18037587.001]
  • [Cites] Am J Clin Oncol. 2008 Jun;31(3):300-5 [18525311.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):357-61 [16012795.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Lancet Neurol. 2008 Dec;7(12):1152-60 [19007739.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1273-80 [16525182.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):419-24 [18272557.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1141-71, x [17964029.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 20842591.001).
  • [ISSN] 1534-3138
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Gaughen JR, Bourne TD, Aregawi D, Shah LM, Schiff D: Focal neuronal gigantism: a rare complication of therapeutic radiation. AJNR Am J Neuroradiol; 2009 Nov;30(10):1933-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report this rare delayed complication in a patient following treatment of a right frontal anaplastic oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Frontal Lobe / pathology. Oligodendroglioma / radiotherapy. Radiation Injuries / pathology. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Gigantism.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574493.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Shirahata M, Oba S, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Ishii S, Takahashi JA, Kato K: Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci; 2009 Jan;100(1):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression levels of these genes in 152 gliomas (100 glioblastomas, 21 anaplastic astrocytomas, 19 diffuse astrocytomas, and 12 anaplastic oligodendrogliomas) were measured using adapter-tagged competitive polymerase chain reaction, a high-throughput reverse transcription-polymerase chain reaction technique.
  • The gene expression profiling identified clinically informative prognostic molecular features in astrocytic and oligodendroglial tumors that were more reliable than the traditional histological classification scheme.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038000.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Ducray F, Dutertre G, Ricard D, Gontier E, Idbaih A, Massard C: [Advances in adults' gliomas biology, imaging and treatment]. Bull Cancer; 2010 Jan;97(1):17-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In anaplastic gliomas ongoing studies depend on 1p/19q codeletion status and in glioblastomas on MGMT methylation status.
  • Advanced brain tumor imaging elicits a better identification of gliomas evolutive potential of.
  • In low-grade gliomas, the importance of maximal resection and the role of chemotherapy are being increasingly recognized.
  • In anaplastic gliomas, phase III studies have clarified the respective roles of chemotherapy and radiotherapy.
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / therapy. Combined Modality Therapy / methods. Diagnostic Imaging / methods. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics. Oligodendroglioma / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028650.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 166
  •  go-up   go-down


35. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol; 2009 Aug;11(4):341-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Codon 132 mutation was seen in 54% of astrocytomas and 65% of oligodendroglial tumors but in only 6% of glioblastomas (3% of primary and 50% of secondary glioblastomas).
  • There were no mutations in any other type of tumor studied.
  • While mutations in the tumor protein p53 gene (TP53) and total 1p/19q deletions were mutually exclusive, IDH1 mutations were strongly correlated with these genetic abnormalities.
  • The data indicate that IDH1 mutation combined with either TP53 mutation or total 1p/19q loss is a frequent and early change in the majority of oligodendroglial tumors, diffuse astrocytomas, anaplastic astrocytomas, and secondary glioblastomas but not in primary glioblastomas.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Isocitrate Dehydrogenase / genetics. Mutation / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Comparative Genomic Hybridization. Exons / genetics. Genotype. Humans. Loss of Heterozygosity. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83 [10560660.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Cell Growth Differ. 2000 Jul;11(7):373-84 [10939591.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Feb;34(2):148-57 [11809417.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Free Radic Res. 2003 Mar;37(3):309-16 [12688426.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Jun;4(6):362-74 [17534392.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • (PMID = 19435942.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ PMC2743214; NLM/ UKMS28703
  •  go-up   go-down


36. Zemanová Z, Kramar F, Babická L, Ransdorfová S, Melichercíková J, Hrabal P, Kozler P, Michalová K: Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH). Folia Biol (Praha); 2006;52(3):71-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH).
  • In oligodendroglial brain tumours, losses of chromosomal material of the short arm of chromosome 1 and long arm of chromosome 19 have been shown to predict responsiveness to chemotherapy and prolonged patients' survival.
  • Therefore, the correct diagnosis of these genetic alterations in tumours of oligodendroglial origin is particularly important.
  • To detect deletions of 1p36 and/or 19q13.3 in oligodendroglial cells we used dual-colour I-FISH with locus-specific DNA probes.
  • We examined 16 patients with histologically proved oligodendrogliomas (5x oligodendroglioma, 9x anaplastic oligodendroglioma, 2x anaplastic oligoastrocytoma).
  • However, in six of them additional genetic alterations typical for high-grade astrocytoma were found, which could have negative influence on the prognosis.
  • A systematic molecular cytogenetic analysis may advance diagnosis, prognostic stratification, and targeted treatment of patients with brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. In Situ Hybridization, Fluorescence. Interphase / physiology. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089917.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


37. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S: Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med; 2005 Dec;19(8):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by gliomas is greater than that by intact tissue, making methionine very useful for evaluation of tumor extent.
  • Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.
  • Tumor activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves.
  • The correlations between methionine uptake and tumor proliferation (tumor versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects.
  • Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031).
  • The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).
  • CONCLUSIONS: When analysis was confined to cases of astrocytic tumor, a correlation was noted between methionine accumulation and Ki-67LI.
  • The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.


38. Gomes AL, Reis-Filho JS, Lopes JM, Martinho O, Lambros MB, Martins A, Schmitt F, Pardal F, Reis RM: Molecular alterations of KIT oncogene in gliomas. Cell Oncol; 2007;29(5):399-408
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KIT, a class III receptor tyrosine kinase (RTK), is frequently involved in tumourigenic processes.
  • Tumour cell immunopositivity was detected in 15.6% (28/179) of cases, namely in 25% (1/4) of pilocytic astrocytomas, 25% (5/20) of diffuse astrocytomas, 20% (1/5) of anaplastic astrocytomas, 19.5% (15/77) of glioblastomas and one third (3/9) of anaplastic oligoastrocytomas.
  • Only 5.7% (2/35) of anaplastic oligodendrogliomas showed CD117 immunoreactivity.
  • In addition, we also observed CD117 overexpression in endothelial cells, which varied from 0-22.2% of cases, being more frequent in high-grade lesions.
  • Interestingly, CISH and/or qRT-PCR analysis revealed the presence of KIT gene amplification in 6 glioblastomas and 2 anaplastic oligoastrocytomas, corresponding to 33% (8/24) of CD117 positive cases.
  • In conclusion, our results demonstrate that KIT gene amplification rather than gene mutation is a common genetic mechanism underlying KIT expression in subset of malignant gliomas.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726262.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4618227
  •  go-up   go-down


39. Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC: YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res; 2006 Oct 1;12(19):5698-704
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
  • PURPOSE: Biomarkers can facilitate diagnosis, monitor treatment response, and assess prognosis in some patients with cancer.
  • YKL-40 and matrix metalloproteinase-9 (MMP-9) are two proteins highly differentially expressed by malignant gliomas.
  • RESULTS: High-grade glioma patients who underwent a surgical resection of their tumor had transient increase of both YKL-40 and MMP-9 serum levels in the postoperative period.
  • Glioblastoma multiforme (GBM) patients with no radiographic evidence of disease (n = 10 patients, 50 samples) had a significantly lower level of YKL-40 and MMP-9 than patients with active tumor (n = 66 patients, 209 samples; P = 0.0003 and 0.0002, respectively).
  • Anaplastic glioma patients with no radiographic evidence of disease (n = 32 patients, 107 samples) also had a significantly lower level of YKL-40 compared with those patients with active tumor (n = 48 patients, 199 samples; P = 0.04).
  • There was a significant inverse association between YKL-40 and survival in GBM, hazard ratio (hazard ratio, 1.4; P = 0.02), and anaplastic astrocytoma patients (hazard ratio, 2.2; P = 0.05).
  • CONCLUSIONS: YKL-40 and MMP-9 can be monitored in patients' serum and help confirm the absence of active disease in GBM and YKL-40 in anaplastic glioma patients.
  • YKL-40 can be used as predictor of survival in patients with high-grade glioma.
  • [MeSH-major] Biomarkers, Tumor / blood. Glioblastoma / blood. Glycoproteins / blood. Matrix Metalloproteinase 9 / blood. Oligodendroglioma / blood

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020973.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Growth Substances; 0 / Lectins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


40. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • OBJECTIVE: To evaluate the usefulness of intraoperative cytology for differential diagnoses of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • In addition, we attempted a computer-assisted image analysis of tumor cell nuclei and compared the results with qualitative observations.
  • Oligodendrogliomas were characterized by small, round nuclei and a fine, delicate capillary network.
  • In both tumors of a higher grade, anaplastic large nuclei and proliferating endothelial cells were noted.
  • Oligoastrocytomas showed combined cytologic profiles of astrocytomas and oligodendrogliomas.
  • Quantitative studies suggested that nuclei of oligodendroglial tumors were significantly rounder than those of astrocytomas.
  • CONCLUSION; Cytologic evaluation using touch or squash preparations is of great help for intraoperative differential diagnosis of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • Cytologic as well as histologic assessment should be conducted at the intraoperative diagnosis of these tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Intraoperative Period. Male. Middle Aged


41. Spampinato MV, Smith JK, Kwock L, Ewend M, Grimme JD, Camacho DL, Castillo M: Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol; 2007 Jan;188(1):204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.
  • OBJECTIVE: The purpose of this study was to determine whether perfusion-weighted imaging (PWI) and proton MR spectroscopy (MRS) are useful in differentiating high- and low-grade oligodendroglial tumors.
  • MATERIALS AND METHODS: PWI and MRS studies of 22 patients with histologically proven oligodendroglioma or oligoastrocytoma (13 low-grade and nine anaplastic tumors) were retrospectively reviewed.
  • RESULTS: Relative cerebral blood volume ratios were significantly different (p = 0.004) between low-grade (1.61 +/- 1.20) and high-grade tumors (5.45 +/- 1.96).
  • The optimal relative cerebral blood volume ratio cutoff value in identification of anaplastic oligodendroglial tumors was 2.14.
  • Analysis of MRS data showed significantly higher Cho/Cr ratios (p = 0.002) in high-grade than in low-grade tumors.
  • A Cho/Cr ratio cutoff value of 2.33 had the highest accuracy in identification of high-grade tumors.
  • CONCLUSION: Relative cerebral blood volume measurement and MRS are helpful in differentiating low-grade from anaplastic oligodendroglial tumors.
  • [MeSH-major] Blood Volume. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179366.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


42. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R: In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res; 2006 Aug 1;12(15):4523-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
  • PURPOSE: Drug resistance in malignant gliomas contributes to poor clinical outcomes.
  • We determined the in vitro drug response profiles for 478 biopsy specimens from patients with the following malignant glial histologies: astrocytoma (n = 71), anaplastic astrocytoma (n = 39), glioblastoma multiforme (n = 259), oligodendroglioma (n = 40), and glioma (n = 69).
  • RESULTS: In vitro drug resistance in malignant gliomas was independent of prior therapy.
  • High-grade glioblastomas showed a lower level of extreme drug resistance than low-grade astrocytomas to cisplatin (11% versus 27%), temozolomide (14% versus 27%), irinotecan (33% versus 53%), and BCNU (29% versus 38%).
  • CONCLUSIONS: Assessment of in vitro drug response and profiles of relevant tumor-associated biomarkers may assist the clinician in stratifying patient treatment regimens.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism
  • [MeSH-minor] Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Carmustine / pharmacology. Cisplatin / pharmacology. DNA Modification Methylases / drug effects. DNA Modification Methylases / genetics. DNA Repair Enzymes / drug effects. DNA Repair Enzymes / genetics. Dacarbazine / pharmacology. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Glutathione S-Transferase pi / drug effects. Glutathione S-Transferase pi / genetics. Humans. Immunohistochemistry. P-Glycoprotein / drug effects. P-Glycoprotein / genetics. P-Glycoproteins. Paclitaxel / pharmacology. Structure-Activity Relationship. Tumor Suppressor Protein p53 / drug effects. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / drug effects. Tumor Suppressor Proteins / genetics. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899598.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 5J49Q6B70F / Vincristine; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 6.5.1.- / DNA Repair Enzymes; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


43. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol; 2009 Dec 10;27(35):5881-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
  • It is unknown if MGMT promoter methylation is also predictive to outcome to RT followed by adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in patients with anaplastic oligodendroglial tumors (AOT).
  • From 165 patients of this study, formalin-fixed, paraffin-embedded tumor tissue was available for MGMT promoter methylation analysis.
  • In multivariate analysis, MGMT promoter methylation, 1p/19q codeletion, tumor necrosis, and extent of resection were independent prognostic factors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2007 Jun;83(2):173-9 [17219056.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):332-7 [18556773.001]
  • [Cites] Neuroepidemiology. 2009;32(1):21-9 [18997474.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1257-61 [19188676.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):348-56 [19224763.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5874-80 [19901110.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):368-81 [17591937.001]
  • [Cites] Lab Invest. 2007 Oct;87(10):1055-65 [17700563.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1105-14 [11844836.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8835-44 [14647440.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Can J Neurol Sci. 1995 May;22(2):111-5 [7627911.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3310-5 [9779706.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4412-7 [16983109.001]
  • [CommentIn] J Clin Oncol. 2009 Dec 10;27(35):5861-2 [19901101.001]
  • (PMID = 19901104.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2793037
  •  go-up   go-down


44. Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB: Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res; 2007 Jun 15;13(12):3559-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant difference existed in percentage and intensity of staining between astrocytic and oligodendroglial tumors (P = 0.0002 and 0.0003, respectively), between grades of tumors (P < 0.0001 and 0.0079), and between pathologic types of tumors (P < 0.0001 and 0.0339).
  • Positive CYP1B1 staining was seen in 81% of glioblastomas, 84% of anaplastic astrocytomas, 61% of oligodendrogliomas, and 67% of anaplastic oligodendrogliomas.
  • Paradoxically, within specific tumor pathologies, there was a trend toward increased survival as CYP1B1 expression increased.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cytochrome P-450 Enzyme System / biosynthesis. Gene Expression. Glioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575219.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
  •  go-up   go-down


45. Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G: Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol; 2009 Jun;53(3):305-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works.
  • The purpose of the present study was to investigate potential prognostic factors in low-grade oligodendrogliomas (LGOs), particularly 1p19q deletion, due to its proven prognostic significance in anaplastic oligodendrogliomas.
  • We carried out a retrospective review of patients with a histological diagnosis of LGO between 1990 and 2000 in Auckland and Wellington, New Zealand.
  • Univariate analysis of potential prognostic factors including 1p19q status, age, tumour size, tumour crossing midline, tumour enhancement, extent of surgery and seizures at diagnosis was carried out.
  • [MeSH-major] Brain Neoplasms. Oligodendroglioma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624298.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 30
  •  go-up   go-down


46. Das S, Chandler JP, Pollack A, Biggio EH, Diaz L, Raizer JJ, Batjer HH: Oligodendroglioma of the pineal region. Case report. J Neurosurg; 2006 Sep;105(3):461-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma of the pineal region. Case report.
  • The authors describe an oligodendroglioma of the pineal region in a 59-year-old woman.
  • Pathological and genetic evaluation showed the tumor to be an anaplastic oligodendroglioma.
  • Although the spectrum of tumors arising within the region of the pineal gland is broad, to the authors' knowledge this is the first report of an oligodendroglioma occurring in this area.
  • [MeSH-major] Brain Neoplasms / pathology. Oligodendroglioma / pathology. Pinealoma / pathology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961143.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E: MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer; 2009 Sep 15;125(6):1407-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.
  • Although the oncogenic and tumor suppressive functions of several miRNAs have been characterized, the role of miRNAs in mediating tumor invasion and migration remains largely unexplored.
  • Here, we performed real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays on 43 glioma samples (17 glioblastoma, 6 anaplastic astrocytoma, 10 low-grade astrocytoma, 6 oligodendroglioma and 4 ependymoma) and 6 glioma cell lines.
  • The expression levels of miR-10b were associated with higher grade glioma.
  • In addition, mRNA expressions of RhoC and urokinase-type plasminogen activator receptor (uPAR), which were thought to be regulated by miR-10b via HOXD10, were statistically significantly correlated with the expression of miR-10b (p < 0.001, p = 0.001, respectively).
  • Finally, multifocal lesions on enhanced MRI of 7 malignant gliomas were associated with higher expression levels of miR-10b (p = 0.02).
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19536818.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LILRB2 protein, human; 0 / Membrane Glycoproteins; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


48. Nafe R, Yan B, Schlote W, Schneider B: Application of different methods for nuclear shape analysis with special reference to the differentiation of brain tumors. Anal Quant Cytol Histol; 2006 Apr;28(2):69-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: At least 300 tumor cell nuclei per case were measured by means of a digital image analysis system.
  • (1) oligodendrogliomas WHO grade II (n = 13) vs. grade III (n = 11), (2) medulloblastomas WHO grade IV (n = 14) vs. anaplastic ependymomas WHO grade III (n = 12), (3) Ki-67-positive vs. Ki-67-negative tumor cell nuclei in the 14 medulloblastomas.
  • CONCLUSION: Fourier analysis provided an optimal statistical discrimination between different brain tumor entities and between data sets from proliferating and nonproliferating tumor cell nuclei.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637509.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Oshiro S, Komatsu F, Tsugu H, Nabeshima K, Abe H, Ohkawa M, Inoue T: [A case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without typical MR appearance for CSF dissemination]. No Shinkei Geka; 2010 Mar;38(3):279-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without typical MR appearance for CSF dissemination].
  • We report a case of intramedullary cervical metastasis from cerebellar anaplastic oligodendroglioma without any MR appearance for CSF dissemination or recurrence in the primary tumor site.
  • The case was a 73-year-old female who underwent tumor resection for cerebellar anaplastic oligodendroglioma following irradiation and TMZ chemotherapy.
  • The histological examination obtained in spinal surgery revealed evidence of similar features consistent with a previous cerebellar tumor with anaplastic oligodendroglioma.
  • Although CSF dissemination by malignant glioma with leptomeningeal enhancement is relatively well recognized at their terminal stage, cases with intramedullary cervical metastasis without any leptomeningeal enhancement have only been rarely described.
  • We discussed the mechanisms of intramedullary cervical metastasis from intracranial malignant glioma.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Oligodendroglioma / pathology. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20229774.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S, Hayashi K, Iwaki T, Sasaki T: Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. Neurol Res; 2007 Oct;29(7):723-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy.
  • OBJECTIVE AND IMPORTANCE: Oligodendroglial tumors rarely occur after radiation therapy.
  • Here, we report a rare case of anaplastic oligodendroglioma arising after radiation therapy, in which genetic analysis was performed.
  • CLINICAL PRESENTATION AND INTERVENTION: A 41-year-old man who had received radiation therapy for a tumor of the suprasellar and pineal regions 31 years previously, presented with headache and progressive right hemiparesis.
  • Total removal of the tumor was performed through left frontoparietal craniotomy, and the histologic diagnosis was anaplastic oligodendroglioma.
  • Based on the genetic analysis, this tumor was considered to be sensitive to chemotherapy.
  • However, tumor recurrence was detected only 3 months after the surgery.
  • Despite additional radiochemotherapy, the tumor aggressively increased in size and the patient died with multiple recurrent tumors 1 year after surgery.
  • CONCLUSION: The anaplastic oligodendroglioma presented in this report showed a more aggressive clinical course than was expected from the genetic analysis.
  • The significance of 1p and 19q LOH in radiation-induced oligodendroglial tumors might differ from that in spontaneous counterparts.
  • [MeSH-major] Brain Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. Frontal Lobe / pathology. Loss of Heterozygosity / genetics. Neoplasms, Radiation-Induced / genetics. Oligodendroglioma / genetics. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Microsatellite Repeats / genetics. Neoplasm Recurrence, Local. Predictive Value of Tests. Treatment Failure


51. Magnani I, Moroni RF, Roversi G, Beghini A, Pfundt R, Schoenmakers EF, Larizza L: Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses. Cancer Genet Cytogenet; 2005 Sep;161(2):140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses.
  • Glioblastomas, the most frequent and malignant glial tumors, are known to be phenotypically heterogeneous.
  • A low fraction of glioblastomas is associated with specific chromosomal losses at 1p and 19q, which are commonly found in oligodendrogliomas and are generally considered to be a primary event in the development of these tumors.
  • Subsequent progression of oligodendroglial tumors appears to be triggered by additional molecular features underlying the transition to anaplastic oligodendroglioma and glioblastoma multiforme (GBM) such as deletions of 9p and 10q, and alterations of CDKN2A (p16), which is located at 9p21.
  • These findings strengthen the view that GBM on rare occasions may develop from oligodendroglial differentiated cells.
  • Genome-wide and chromosome 19 full coverage array-CGH analysis of the MI-4 cell line revealed that in this particular cell line, 1p-specific loss, including the CDKN2 (p18) gene, is not accompanied by loss of the previously described 19q13.3 tumor suppressor candidate region.
  • The concomitant 1p partial loss and chromosome 19 alterations, with the +7 and -10-specific GBM markers associated with homozygous deletion of 9p21.3 including CDKN2A (p16), are distinct features of the glioblastoma MI-4 cell line, illustrating its origin from an olidodendroglial tumor.
  • Based on these results, we conclude that the MI-4 glioblastoma cell line might function as a model system for investigations into the behavior of a defined oligodendroglioma subtype.
  • [MeSH-major] Brain Neoplasms / genetics. Cell Line, Tumor. Chromosome Aberrations. Chromosomes, Human, Pair 1. Glioblastoma / genetics. Oligodendroglioma / genetics


52. Jin YH, Jung S, Jin SG, Jung TY, Moon KS, Kim IY: GRIM-19 Expression and Function in Human Gliomas. J Korean Neurosurg Soc; 2010 Jul;48(1):20-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We determined whether the expression of GRIM-19 is correlated with pathologic types and malignant grades in gliomas, and determined the function of GRIM-19 in human gliomas.
  • METHODS: Tumor tissues were isolated and frozen at -80 just after surgery.
  • The tissues consisted of normal brain tissue (4), astrocytomas (2), anaplastic astrocytomas (2), oligodendrogliomas (13), anaplastic oligodendrogliomas (11), and glioblastomas (16).
  • To profile tumor-related genes, we applied RNA differential display using a Genefishing DEG kit, and validated the tumor-related genes by reverse transcription polymerase chain reaction (RT-PCR).
  • The morphologic and cytoskeletal changes were examined via light and confocal microscopy.
  • RESULTS: Based on RT-PCR analysis, the expression of GRIM-19 was higher in astrocytic tumors than oligodendroglial tumors.
  • The expression of GRIM-19 was higher in high-grade tumors than low-grade tumors or normal brain tissue; glioblastomas showed the highest expression.
  • The antisense-transfection cells became smaller and rounder compared with wild type U343MG-A.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] J Biol Chem. 1999 Sep 17;274(38):26783-8 [10480883.001]
  • [Cites] J Virol. 1998 Feb;72(2):1043-51 [9444998.001]
  • [Cites] Trends Genet. 1999 May;15(5):179-84 [10322484.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1693s-1700s [10197582.001]
  • [Cites] Haematologica. 1998 Sep;83(9):771-7 [9825572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15623-8 [9861020.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):931-7 [9815768.001]
  • [Cites] Annu Rev Biochem. 1998;67:227-64 [9759489.001]
  • [Cites] Neurol Res. 1997 Dec;19(6):623-8 [9427964.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Science. 1997 Nov 28;278(5343):1630-2 [9374464.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19457-63 [9235947.001]
  • [Cites] Cell Growth Differ. 1997 Jun;8(6):687-98 [9186002.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):9742-8 [9092506.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):222-32 [9069256.001]
  • [Cites] Blood. 1997 Feb 1;89(3):1001-12 [9028332.001]
  • [Cites] Blood. 1996 Nov 15;88(10):3926-36 [8916959.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2027-33 [8609713.001]
  • [Cites] Cell. 1995 Dec 15;83(6):841-50 [8521508.001]
  • [Cites] Curr Opin Cell Biol. 1994 Dec;6(6):825-31 [7880529.001]
  • [Cites] Semin Hematol. 1994 Oct;31(4 Suppl 5):31-7 [7831583.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(19):8447-56 [15367666.001]
  • [Cites] Biotechniques. 2004 Mar;36(3):424-6, 428, 430 passim [15038158.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2474-81 [15059901.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9342-7 [12867595.001]
  • [Cites] Front Biosci. 2003 May 1;8:e281-8 [12700122.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1325-35 [12628925.001]
  • [Cites] J Interferon Cytokine Res. 2002 Oct;22(10):1017-26 [12433281.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38345-8 [11522775.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33416-26 [10924506.001]
  • [Cites] J Interferon Cytokine Res. 2000 Jul;20(7):661-5 [10926209.001]
  • [Cites] Histol Histopathol. 2000 Apr;15(2):523-37 [10809374.001]
  • [Cites] Cell Signal. 2010 Feb;22(2):212-20 [19788921.001]
  • [Cites] Br J Neurosurg. 2007 Oct;21(5):496-500 [17852105.001]
  • [Cites] Oncogene. 2007 Jul 19;26(33):4842-9 [17297443.001]
  • [Cites] Oncogene. 2006 Nov 16;25(54):7138-47 [16732315.001]
  • [Cites] Cancer Treat Rev. 2006 Apr;32(2):74-89 [16488082.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1892-8 [15841082.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [9636188.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6493-504 [9774665.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] Science. 1998 Mar 6;279(5356):1547-51 [9488655.001]
  • (PMID = 20717508.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2916144
  • [Keywords] NOTNLM ; Cell line / GRIM-19 / Gene Fishing / Glioblastoma / Human glioma
  •  go-up   go-down


53. Berbos ZJ, Lee MS, Zaldivar RA, Pambuccian S, Harrison AR: Intravascular lymphoma presenting as an orbital mass lesion: a case report. Orbit; 2010 Apr;29(2):91-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain biopsy was interpreted as anaplastic oligodendroglioma.
  • On review of brain histopathology, the diagnosis was revised to CNS intravascular lymphoma.
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394547.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


54. Kronik N, Kogan Y, Vainstein V, Agur Z: Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother; 2008 Mar;57(3):425-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
  • Glioblastoma (GBM), a highly aggressive (WHO grade IV) primary brain tumor, is refractory to traditional treatments, such as surgery, radiation or chemotherapy.
  • Our model encompasses considerations of the interactive dynamics of aCTL, tumor cells, major histocompatibility complex (MHC) class I and MHC class II molecules, as well as cytokines, such as TGF-beta and IFN-gamma, which dampen or increase the pro-inflammatory environment, respectively.
  • The mathematical model successfully retrieved clinical trial results of efficacious aCTL immunotherapy for recurrent anaplastic oligodendroglioma and anaplastic astrocytoma (WHO grade III).
  • Model analysis suggests that GBM may be eradicated by new dose-intensive strategies, e.g., 3 x 10(8) aCTL every 4 days for small tumor burden, or 2 x 10(9) aCTL, infused every 5 days for larger tumor burden.
  • Further analysis pinpoints crucial bio-markers relating to tumor growth rate, tumor size, and tumor sensitivity to the immune system, whose estimation enables regimen personalization.
  • Re-initiation of clinical trials, using calculated individualized regimens for grade III-IV malignant glioma, is suggested.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Immunol Immunother. 2008 Mar;57(3):441
  • (PMID = 17823798.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


55. Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, Benson A, Woods AM, Cher L: A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro Oncol; 2010 May;12(5):500-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
  • Glial tumors with oligodendroglial components are considered chemo-responsive.
  • Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 every 4 weeks for 6 cycles).
  • Only 18% of the patients (7 of 40) experienced treatment-related grade 3/4 toxicities.
  • These data add to the growing body of data showing that primary chemotherapy may be an acceptable alternative to radiotherapy for patients with gliomas containing oligodendroglial histology.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Female. Gene Deletion. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Middle Aged. Tumor Suppressor Proteins / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):242-51 [17284109.001]
  • [Cites] Nucleic Acids Res. 2007;35(6):e41 [17289753.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):262-72 [18272388.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4189-99 [18757334.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):57-63 [19011763.001]
  • [Cites] Neuro Oncol. 2009 Apr;11(2):167-75 [18779504.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Aug;60(8):808-16 [11487055.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • (PMID = 20406900.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2940620
  •  go-up   go-down


56. Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL: Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol; 2007 May;83(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.
  • PURPOSE: To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy.
  • PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
  • Complete resection and cerebral tumor location was associated with better overall survival (OS) in patients with institutional diagnoses of AMG.
  • However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or anaplastic mixed oligoastrocytoma (AOA) and only one had AO.
  • CONCLUSION: Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Hepatology. 1991 Nov;14(5):751-5 [1937381.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] J Neurooncol. 1994;21(3):255-65 [7699420.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] J Neurooncol. 2003 May;63(1):49-54 [12814254.001]
  • [Cites] J Chronic Dis. 1967 Aug;20(8):637-48 [4860352.001]
  • [Cites] J Neurooncol. 1988;6(1):9-23 [3294353.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Pediatr Neurosurg. 2003 Sep;39(3):114-21 [12876389.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Nov;53(6):559-71 [7964897.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S120-3 [2231292.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • (PMID = 17252186.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


57. Smith SF, Simpson JM, Brewer JA, Sekhon LH, Biggs MT, Cook RJ, Little NS: The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients. J Neurooncol; 2006 Oct;80(1):75-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients.
  • Accurate prognosis for patients with anaplastic oligodendroglial gliomas is increasingly difficult to make.
  • Characterisation of these tumours remains challenging, increasing proportions of oligodendroglial diagnoses in gliomas are reported, and no WHO 2000 grade IV exists for them, so that highly anaplastic tumours can only be grouped with glioblastoma (GBM) or with grade III oligodendroglioma, which have differing clinical behaviour.
  • Longer survival times reported for patients with glioblastoma containing an oligodendroglial element (GBMO) suggest that a grade IV for oligodendroglial tumours might exist.
  • In patients with anaplastic gliomas containing an oligodendroglial element, we explored whether microvascular proliferation (MVP) and necrosis were associated with shorter survival, sufficient to create a grade IV.
  • Biopsies for 98 patients with anaplastic oligodendroglioma, anaplastic oligoastrocytoma or tumours with an oligodendroglial and GBM element, discharged 1998-2004, were identified from databases at three allied neurosurgery units.
  • Anaplastic oligoastrocytoma and GBMO were combined to measure the effect of an astrocytic element on survival.
  • For anaplastic oligodendroglioma patients, median survival time was 24 months, while for anaplastic oligoastrocytoma or GBMO patients, it was 9 months.
  • Patients 60 and over with an astrocytic element had 4.6 times the risk of death of patients under 60 with anaplastic oligodendroglioma.A grade IV cannot be created using necrosis or MVP since neither feature predicted survival after adjustment for age and an astrocytic element.
  • However age and an astrocytic element were strong predictors of poorer survival in patients with anaplastic oligodendroglial tumours.
  • [MeSH-major] Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Oligodendroglioma / blood supply. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):915-20; discussion 921 [16326271.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):61-78 [9210053.001]
  • [Cites] J Neuropathol Exp Neurol. 1986 Jan;45(1):65-78 [3941327.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]
  • [Cites] J Clin Neurosci. 2004 Jan;11(1):31-6 [14642362.001]
  • [Cites] J Neurol. 2000 Jun;247(6):455-60 [10929275.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Cancer. 1988 Jun 1;61(11):2251-9 [3365653.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Oct;29(5):462-71 [14507338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Adv Anat Pathol. 2001 Jul;8(4):183-99 [11444508.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1204-12 [2205356.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1345-52 [3545437.001]
  • [Cites] J Neurooncol. 1999 Sep;44(2):99-107 [10619493.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):196-201 [11801559.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2107-14 [6627218.001]
  • (PMID = 16794749.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Kim SJ, Park TS, Lee ST, Song J, Suh B, Kim SH, Jang SJ, Lee CH, Choi JR: Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. Ann Clin Lab Sci; 2009;39(4):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases included anaplastic astrocytoma (4 cases), anaplastic oligodendroglioma (2 cases), low grade astrocytoma (2 cases), low grade oligodendroglioma (1 case), and one case of secondary Philadelphia-positive acute lymphoblastic leukemia in a patient with glioblastoma multiforme.


59. Cetin N, Dienel G, Gokden M: CD117 expression in glial tumors. J Neurooncol; 2005 Nov;75(2):195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proportion of high grade tumors of all tumor types with detectable CD117 immunoreactivity was statistically significantly greater than low grade tumors, and glioblastoma and anaplastic oligodendroglioma showed the highest staining grade.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6139-43 [1384954.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):56-61 [12610358.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Oct;3(5):595-614 [14599084.001]
  • [Cites] J Neurosurg. 1987 Nov;67(5):697-705 [3668638.001]
  • [Cites] J Pharmacokinet Biopharm. 1980 Jun;8(3):257-96 [7420270.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Exp Neurol. 1996 Oct;141(2):214-24 [8812155.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5114-7 [12941842.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Aug;25(8):644-8 [12902920.001]
  • [Cites] J Neurosci Res. 1993 Dec 1;36(5):596-606 [7511700.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Mar;11(1):51-5 [12610357.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):177-83 [12134909.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):325-7 [12645332.001]
  • [Cites] Brain Res Mol Brain Res. 1992 Sep;15(1-2):47-54 [1331669.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):327-33 [9440029.001]
  • [Cites] Am J Hematol. 2000 Nov;65(3):234-8 [11074541.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3132-8 [7579408.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1241-9 [14977821.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S11-20 [15036937.001]
  • [Cites] Acta Neuropathol. 1995;89(2):158-65 [7537428.001]
  • [Cites] Oncogene. 1998 Aug 13;17(6):795-800 [9715282.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3498-502 [1375870.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Microsc Res Tech. 1994 Apr 15;27(6):516-27 [8012054.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jul;1(7):493-502 [12120256.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5143-50 [11016641.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Feb;4(1):105-28 [14748662.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):339-45 [12645334.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):486-92 [11914627.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(3):387-400 [10721492.001]
  • [Cites] Ann Hematol. 2001 May;80(5):302-7 [11446735.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92 [12604685.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1063-73 [7514661.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):106-15 [7689190.001]
  • [Cites] J Neurosci Res. 1997 Jan 1;47(1):1-15 [8981233.001]
  • [Cites] Eur J Neurosci. 2002 Feb;15(3):575-82 [11876786.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):188-93 [11865845.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):311-9 [12163450.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jan 31;182(2):474-80 [1370880.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):1013-9 [12826896.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):339-46 [7678721.001]
  • [Cites] Oncology. 2003;65(3):187-97 [14657591.001]
  • [Cites] Cancer Invest. 2004;22(1):106-16 [15069768.001]
  • [Cites] Adv Exp Med Biol. 2003;532:141-51 [12908555.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):870-2 [11821475.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):106-8 [12358909.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Oct;3(5):655-70 [14599089.001]
  • (PMID = 16132504.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS38230
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


60. Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K: Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res; 2007 Dec 15;13(24):7341-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.
  • In this study, we focused on anaplastic oligodendroglioma and glioblastoma, which typically follow distinct clinical courses.
  • EXPERIMENTAL DESIGN: The expression of 3,456 genes in 32 patients, 12 and 20 of whom had prognostically distinct anaplastic oligodendroglioma and glioblastoma, respectively, was measured by PCR array.
  • Next to unsupervised methods, we did supervised analysis using a weighted voting algorithm to construct a diagnostic system discriminating anaplastic oligodendroglioma from glioblastoma.
  • The clinical utility was tested on a microarray-based data set of 50 malignant gliomas from a previous study.
  • RESULTS: Unsupervised analysis showed divergent global gene expression patterns between the two tumor classes.
  • Applied to a gene expression data set from a previous study, our model correlated better with outcome than histologic diagnosis, and also displayed 96.6% (28 of 29) consistency with the molecular classification scheme used for these histologically controversial gliomas in the original article.
  • Furthermore, we observed that histologically diagnosed glioblastoma samples that shared anaplastic oligodendroglioma molecular characteristics tended to be associated with longer survival.
  • CONCLUSIONS: Our molecular diagnostic system showed reproducible clinical utility and prognostic ability superior to traditional histopathologic diagnosis for malignant glioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Glioblastoma / diagnosis. Glioblastoma / genetics. Oligodendroglioma / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094416.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Xiong J, Liu Y, Li C, Zhu JJ, Ye ZR, Mao Y, Wang Y: [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):445-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
  • OBJECTIVE: To study the status of loss of heterozygosity (LOH) of chromosome 1p/19q and p53 protein expression in oligodendroglioma, as compared to astrocytoma.
  • METHODS: One hundred and ninety-one cases of glioma of different histologic types and grades, including 116 cases of low-grade of oligodendroglioma (86 paraffin-embedded and 30 fresh tissues), 45 cases of anaplastic oligodendroglioma (all paraffin-embedded tissues) and 30 cases of astrocytoma of various grades (all paraffin-embedded tissues), were enrolled into the study.
  • RESULTS: The rates of 1p loss, 19q loss and 1p/19q loss were 69.8%, 64%, and 57.0% respectively in the 86 paraffin-embedded low-grade oligodendroglioma samples, as compared to 71.1%, 60.0% and 55.6% respectively in the 45 paraffin-embedded anaplastic oligodendroglioma samples.
  • There was no difference of LOH of 1p/19q between low-grade oligodendroglioma and anaplastic oligodendroglioma (P>0.05).
  • In the 30 cases of low-grade oligodendroglioma with fresh tissues available, the rates of 1p loss, 19q loss and 1p/19q loss were 70.0%, 63.3% and 60.0% respectively.
  • In the 30 cases of astrocytoma, the rates of 1p loss, 19q loss and 1p/19q loss were 23.3%, 33.3% and 20.0% respectively, which were significantly less than those in oligodendroglioma (P<0.05).
  • The expression of p53 protein was significantly lower in low-grade oligodendroglioma (8.1%) than in anaplastic oligodendroglioma (31.1%, P=0.007).
  • The expression of p53 protein in oligodendroglioma was also lower than in astrocytoma (P=0.001).
  • Furthermore, p53 protein expression negatively correlated with 1p/19q loss in anaplastic oligodendroglioma (P<0.05).
  • Oligodendroglioma demonstrates a higher frequency of LOH of chromosome 1p/19q and lower expression of p53 protein than astrocytoma.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Loss of Heterozygosity. Oligodendroglioma / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


62. Takeuchi Y, Kanamori M, Kumabe T, Saito R, Sonoda Y, Watanabe M, Tominaga T: Collision tumor of anaplastic oligodendroglioma and gangliocytoma: a case report. Brain Tumor Pathol; 2009;26(2):89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of anaplastic oligodendroglioma and gangliocytoma: a case report.
  • A 53-year-old woman presented with a rare case of coexistence of anaplastic oligodendroglioma with gangliocytoma manifesting as progressive disturbance of consciousness and left hemiparesis.
  • She underwent subtotal resection of the tumor, resulting in improvement of her symptoms.
  • Macroscopic and histological examination showed the tumor consisted of two distinct components, grayish soft tissue and yellowish hard tissue.
  • The former consisted of cells with equal-sized round-to-oval hyperchromatic nuclei and perinuclear halo with microvascular proliferation and necrosis, and the diagnosis was anaplastic oligodendroglioma.
  • The latter consisted of large and dysplastic neurons with marked nucleoli and basophilic cytoplasm containing Nissl bodies, with nonneoplastic glial cells in the stroma, and the diagnosis was gangliocytoma.
  • These two tumors apparently occurred as a collision tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ganglioneuroma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Oligodendroglioma / diagnosis. Temporal Lobe / pathology


63. Uzuka T, Kakita A, Inenaga C, Takahashi H, Tanaka R, Takahashi H: Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report. Neurol Med Chir (Tokyo); 2007 Apr;47(4):174-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report.
  • A 17-year-old woman presented with an anaplastic oligodendroglioma manifesting as generalized seizure.
  • Neuroimaging studies revealed a right frontal tumor.
  • Histological examinations of biopsy specimens revealed that the tumor was oligodendroglial in nature.
  • Total resection was repeated four times, and malignant change was evident within the tissues.
  • The final diagnosis was anaplastic oligodendroglioma.
  • Despite irradiation, combination chemotherapy, and interstitial hyperthermia, the tumor grew rapidly but was confined to the cavity created by previous removal operations.
  • At autopsy, generalized metastases from the tumor were identified at various sites, including the dura mater covering the frontal lobes and thoracic cord, cavernous sinus, tuberculum sellae, spleen, liver, pancreas, lungs, paratracheal lymph nodes, vertebral bodies, ribs, sternum, pelvis, dorsal root ganglia, and iliopsoas muscle.
  • This rare case of cerebral anaplastic oligodendroglioma developed in adolescence, and rapid hematogenous spread of the glioma cells into the systemic organs occurred after a relatively long clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe. Oligodendroglioma / secondary


64. Chamberlain MC, Chowdhary SA, Glantz MJ: Anaplastic astrocytomas: biology and treatment. Expert Rev Neurother; 2008 Apr;8(4):575-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytomas: biology and treatment.
  • Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms.
  • The most important predictor of response to therapy and survival in AA tumors is the presence or absence of the 1p19q co-deletion, a translocation that defines a subset of oligodendroglial tumors, and anaplastic oligodendrogliomas in particular.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416660.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • PURPOSE: Patients with anaplastic gliomas have a more favorable overall survival than patients with glioblastomas.
  • In most analyses, WHO grade III and 1V tumors are not analyzed separately.
  • The present analysis reports outcome after postoperative radiotherapy in patients with WHO grade III gliomas.
  • PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients.
  • After the primary diagnosis, a biopsy had been performed in 72 patients; subtotal and total resections were performed in 37 and 18 patients, respectively.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol; 2007 Apr;14(4):391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
  • Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed.
  • Several studies have reported the efficacy of various chemotherapeutic agents in a small number of patients with low-grade gliomas, e.g. pure astrocytomas, OG or mixed histologies.
  • We report the outcome of 33 consecutive patients with pure low-grade OG diagnosed between 1990 and 2006 systematically treated for residual or non-removable tumor with PCV chemotherapy regimen as the front-line treatment after surgery.
  • All the tumors were low grade (grade II) pure OG according to the WHO classification.
  • All patients were symptomatic at presentation and underwent neurosurgical procedure for histological diagnosis.
  • Twenty-one men and 12 women with a mean age at pathological diagnosis of 46.5 years were studied.
  • Eleven patients (36%) had a malignant transformation during the follow-up with a median time to progression of 19 months.
  • Up-front chemotherapy with PCV regimen is a good treatment for symptomatic pure low-grade OG, as it increases the number of progression-free patients and time to progression.
  • These results suggest that radiotherapy could be postponed until the malignant transformation occurs to delay cognitive side effects of irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388986.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


67. Hughes MA, Parisi M, Grossman S, Kleinberg L: Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: CD4 counts were measured during RT in 70 of 76 consecutive patients with newly diagnosed Grade III and IV astrocytoma and anaplastic oligodendroglioma treated with corticosteroids and seen at the Johns Hopkins Hospital.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029802.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


68. Bunevicius A, Deltuva VP, Deltuviene D, Tamasauskas A, Bunevicius R: Brain lesions manifesting as psychiatric disorders: eight cases. CNS Spectr; 2008 Nov;13(11):950-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study presents eight cases of patients with brain lesions (four cases of meningiomas, one case of intracerebral cysts, one case of anaplastic oligodendroglioma, one case of multiform glioblastoma, and one case of occlusive hydrocephalus) who, for a significant period of time, were diagnosed and treated for psychiatric disorders (three cases of Alzheimer's disease, two cases of schizoaffective disorder, one case of schizophrenia, one case of depression, and one case of organic emotional lability disorder).
  • [MeSH-major] Brain Neoplasms / pathology. Cognition Disorders / etiology. Glioblastoma / complications. Glioblastoma / pathology. Oligodendroglioma / complications. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037181.001).
  • [ISSN] 1092-8529
  • [Journal-full-title] CNS spectrums
  • [ISO-abbreviation] CNS Spectr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ: Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol; 2007 Jun;66(6):545-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
  • The diagnosis of anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) is subject to interobserver variation.
  • The aim of this study was to estimate consensus in typing and grading of these tumors using tumor material collected in a large prospective randomized phase III study and to correlate the consensus diagnosis with the 1p/19q status of the tumors and the clinical outcome.
  • The panel reached consensus on the diagnosis of AOD in 52% of the tumors that had been diagnosed as AOD by the local pathologists, whereas only 8% of the local diagnosis of AOA was confirmed with consensus.
  • The concordance on the panel diagnosis of AOD was high (intraclass correlation = 86%).
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Deletion. Oligodendroglioma / genetics. Oligodendroglioma / pathology


70. Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F: Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? Neuro Oncol; 2010 May;12(5):490-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
  • The purpose of this study was to determine whether chromosome 10q loss is a predictor of tumor aggressiveness and poor clinical outcome in patients with oligodendroglial tumors alone or together with loss of heterozygosity (LOH) on chromosomes 1p and 19q.
  • A microsatellite analysis was performed on sections from 130 patients with grade II and grade III oligodendroglial tumors to assess the allelic status of chromosomes 1p, 19q, and 10q, plus detailed clinical and radiological information was taken prospectively.
  • Median age at diagnosis was 45.5 years.
  • Age <47 years, postoperative Karnofsky performance score >65, no contrast enhancement on MRI, grade II, and complete removal on surgery were significantly correlated with a better PFS.
  • Pure oligodendroglioma and temozolomide chemotherapy were correlated with better OS.
  • 10q LOH was correlated with anaplastic grade and 1p19q LOH correlated with pure oligodendroglioma.
  • 10q LOH predicted a survival disadvantage in patients with oligodendroglial tumors irrespective of 1p/19q LOH status.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm / genetics. Female. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Precision Medicine / methods. Prognosis. Young Adult


71. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer; 2005 Feb 15;103(4):802-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
  • BACKGROUND: Anaplastic oligodendroglioma (OD) tumors, especially those with the combined loss of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), are sensitive to chemotherapy.
  • Only limited data are available on the role of chemotherapy in low-grade OD.
  • The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD.
  • METHODS: Two groups of patients were studied: newly diagnosed patients with large OD and mixed oligoastrocytomas (OA) and patients with recurrent OD and OA after radiotherapy who still showed nonenhancing tumors.
  • Several patients showed a signficant clinical improvement despite only a modest improvement of the tumor on the MRI scans.
  • A Phase III trial should be initiated to compare radiotherapy with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction. Procarbazine / therapeutic use. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 15637687.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


72. Owen CM, Linskey ME: Frame-based stereotaxy in a frameless era: current capabilities, relative role, and the positive- and negative predictive values of blood through the needle. J Neurooncol; 2009 May;93(1):139-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnostic accuracy was calculated comparing biopsy diagnosis with final pathology in 11 patients who underwent subsequent surgical resection.
  • Of 18 lesions involving the corpus callosum, 13 (72.2%) were GBM 2 were anaplastic astrocytoma, and 1 each were found to be anaplastic oligodendroglioma, primary central nervous system lymphoma (PCNSL) and tumescent MS.
  • Of 25 multifocal lesions, malignant primary brain tumor was diagnosed in 17 (68%) (11 GBM, 3 PCNSL, 2 anaplastic ologodendroglioma, and 1 anaplastic astrocytoma).
  • CONCLUSIONS: Stereotactic biopsy is an effective, safe and important technique for histologic diagnosis of brain lesions, particularly for multifocal and corpus callosum lesions.
  • Post-biopsy CT can be safely reserved for patients who demonstrate persistent bleeding through the biopsy needle.
  • [MeSH-major] Biopsy, Needle / methods. Brain Diseases / diagnosis. Brain Diseases / surgery. Neuronavigation
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comput Aided Surg. 1998;3(2):51-6 [9784952.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Mar;45(1):11-5 [11932818.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):830-5; discussion 835-7 [11564243.001]
  • [Cites] Br J Neurosurg. 2006 Aug;20(4):222-6 [16954072.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):170-6; discussion 176-8 [8747966.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS146-56; discussion ONS146-56 [16888546.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1985;35:70-4 [3911747.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):368-72 [7850537.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12 (6):1165-75 [1763744.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):233-7 [16509497.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):31-5 [9647169.001]
  • [Cites] J Neurooncol. 2005 Jun;73(2):173-9 [15981109.001]
  • [Cites] Appl Neurophysiol. 1982;45(4-5):426-30 [7036878.001]
  • [Cites] Surg Neurol. 1984 Sep;22(3):222-30 [6379944.001]
  • [Cites] Surg Neurol. 1980 Oct;14(4):275-83 [7001660.001]
  • [Cites] J Neurosurg. 2005 May;102(5):897-901 [15926716.001]
  • [Cites] Neurosurg Rev. 1994;17 (1):59-66 [8078610.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):65-70 [16132501.001]
  • [Cites] J Clin Neurosci. 2004 Apr;11(3):263-7 [14975414.001]
  • [Cites] Neurosurgery. 1987 Jun;20(6):930-7 [3302751.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):907-12; discussion 912-4 [8905744.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):193-200 [11465400.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):110-8 [12046728.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):165-8 [8027795.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):358-62 [15949232.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):370-87 [12186466.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):682-94; discussion 694-5 [7808612.001]
  • [Cites] J Neurosurg. 2001 Apr;94(4):545-51 [11302651.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):160-8 [10413173.001]
  • [Cites] Neurosurgery. 1983 Mar;12 (3):277-85 [6341870.001]
  • [Cites] Surg Neurol. 2001 Dec;56(6):366-71; discussion 371-2 [11755966.001]
  • [Cites] Acta Neurochir (Wien). 1981;57(3-4):213-34 [6269368.001]
  • (PMID = 19430891.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


73. Quon H, Abdulkarim B: Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev; 2008;(2):CD007104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
  • Outcomes analyzed include overall survival (OS), progression-free survival (PFS), and treatment toxicity greater than or equal to grade 3.
  • Based on the differences in patient selection with respect to the definition of AO (2 versus 3 high risk anaplastic features) and sequence of treatment (RT and chemotherapy), the results from the two RCTs were not able to be considered for meta-analysis.
  • Tumors with 1p and 19q co-deletions are associated with better OS and may indicate a more chemo-responsive tumor.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;5:CD007104 [24833028.001]
  • (PMID = 18425979.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 11
  •  go-up   go-down


74. Peria FM, Neder L, Marie SK, Rosemberg S, Oba-Shinjo SM, Colli BO, Gabbai AA, Malheiros SM, Zago MA, Panepucci RA, Moreira-Filho CA, Okamoto OK, Carlotti CG Jr: Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival. J Neurooncol; 2007 Sep;84(3):255-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival.
  • BACKGROUND: Pleiotrophin (PTN) is a secreted cytokine with several properties related with tumor development, including differentiation, angiogenesis, invasion, apoptosis and metastasis.
  • Astrocytic and oligodendroglial tumors are the most frequent primary brain neoplasms.
  • Astrocytic tumors are classified as pilocytic astrocytoma (PA), diffuse astrocytoma (DA), anaplastic astrocytoma (AA) and glioblastoma (GBM).
  • Oligodendroglial tumors are classified as oligodendroglioma (O) and anaplastic oligodendroglioma (AO).
  • The aim of the present study was to compare PTN expression, in astrocytomas and oligodendrogliomas and its association with the histological diagnosis, microvascular density, proliferate potential and clinical outcome.
  • The histological diagnosis in accordance with WHO classification was: 13PA, 18DA, 8AA, 15GBM, 16O and 8AO.
  • Proliferate index and microvascular density were evaluated only in high grade tumors (AA, GBM and AO) divided in three groups according to PTN expression (low, intermediate and high).
  • Overall survival (OS) analysis (months) showed similar results in high grade gliomas with different levels of PTN expression.
  • CONCLUSIONS: Our results suggest that PTN expression is associated with histopathological grade of astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / pathology. Carrier Proteins / biosynthesis. Cytokines / biosynthesis. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] FASEB J. 2004 Aug;18(11):1237-9 [15180956.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 5;343(2):653-8 [16554021.001]
  • [Cites] Growth Factors. 1994;10(2):89-98 [7520717.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] J Neurochem. 2006 Sep;98(5):1497-506 [16923162.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Dec;62(12):1265-75 [14692702.001]
  • [Cites] J Neurochem. 2002 Nov;83(4):747-53 [12421346.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6661-8 [14555979.001]
  • [Cites] J Cutan Pathol. 2005 Feb;32(2):125-30 [15606670.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] Gene Ther. 2005 Feb;12(4):339-46 [15496960.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):10663-8 [16507572.001]
  • [Cites] Arch Biochem Biophys. 2002 Jan 15;397(2):162-71 [11795867.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):16721-4 [2170351.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2271-8 [16489031.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26953-64 [15908427.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):637-43; discussion 644-5 [15684595.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):289-97 [12648577.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Sep 17;152(2):189-97 [15351507.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35862-8 [12107166.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1468-73 [9776412.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9180-91 [15632143.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):858-63 [11953815.001]
  • (PMID = 17443289.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cytokines; 134034-50-7 / pleiotrophin
  •  go-up   go-down


75. Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, Gonzalez Leon P, Ricoy Campo JR: Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis. Clin Neuropathol; 2009 Jan-Feb;28(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.
  • BACKGROUND: The clinical course of oligodendroglial tumors is variable and there is a lack of consensus with regard to precisely diagnose which minimal criteria are required to make a diagnosis of a high-grade oligodendrial tumor.
  • The aims of the present study are to assess pathologic factors with prognostic significance, in addiction to clinical and neuroradiologic variables, in an attempt to identify reproducible histological parameters that are useful for classification of oligodendroglial tumors.
  • METHODS: 80 oligodendroglial tumors diagnosed between 1977 and 2004 were analyzed.
  • To make a diagnosis of anaplastic tumor we used reproducible parameters: endothelial proliferation, high cellularity, increased mitotic activity and necrosis.
  • RESULTS: The histologic diagnosis was low-grade oligodendroglioma in 35 patients (43.75%), anaplastic oligodendroglioma in 23 patients (28.75%), low-grade oligoastrocytoma in 11 patients (13.75%) and anaplastic oligoastrocytoma in 11 patients (13.75%).
  • The median overall survival of oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma and anaplastic oligoastrocytoma was 148, 105, 47 and 7 months, respectively (p < 0.0001).
  • Multivariate analysis revealed that age, Karnofsky performance status, histological grade and histological diagnosis (oligodendroglioma vs. oligoastrocytoma) were independently associated with survival.
  • CONCLUSIONS: Clear cut histopathological criteria (endothelial proliferation, high cellularity, mitotic activity and necrosis) allow to establish different oligodendroglial tumor entities with distinct survival outcome.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Neuropathol. 2009 Mar-Apr;28(2):150
  • (PMID = 19216215.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


76. Levin VA, Ictech S, Hess KR: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer; 2007;7:106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.
  • BACKGROUND: To assess progression-free survival (PFS) as the appropriate end-point for phase II trials for anaplastic gliomas (AGs) and to determine the impact of PFS on survival-based phase III trials.
  • CONCLUSION: Based on PFS rates at 6, 9, and 12 months for AG patients, a differential of 1.5 to 2 years is the norm and could invalidate overall survival as an end-point for phase III studies in patients with AG.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Oligodendroglioma / drug therapy. Oligodendroglioma / mortality

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2604-13 [10561328.001]
  • [Cites] Neurology. 1984 May;34(5):615-9 [6538653.001]
  • [Cites] Cancer Treat Rep. 1984 Jul-Aug;68(7-8):969-73 [6744348.001]
  • [Cites] Neurology. 1985 Feb;35(2):219-26 [3969210.001]
  • [Cites] J Neurooncol. 1985;3(1):19-21 [2987424.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1497-501 [4040799.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):799-806 [3021932.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):464-71 [3029339.001]
  • [Cites] Am J Clin Oncol. 1988 Feb;11(1):52-4 [2829615.001]
  • [Cites] J Neurooncol. 1988 Dec;6(4):319-23 [3221259.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2420-3 [2555038.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurooncol. 1991 Feb;10(1):27-30 [1902506.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1945-9 [1658242.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1432-7 [1380989.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4):715-26 [7611028.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):1983-7 [8616836.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):145-51 [9210061.001]
  • [Cites] Neurology. 1998 Mar;50(3):777-81 [9521274.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):309-17 [10037179.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):83-90 [16639492.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Radiology. 2000 Nov;217(2):377-84 [11058631.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] J Cell Biol. 2001 Mar 5;152(5):971-84 [11238453.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):981-90 [12631596.001]
  • [Cites] Cancer Res. 1970 Oct;30(10):2451-5 [5474173.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] Cancer. 1975 Jun;35(6):1551-7 [1148989.001]
  • [Cites] Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):327-31 [1149010.001]
  • [Cites] Adv Neurol. 1976;15:315-25 [779423.001]
  • [Cites] J Neurosurg. 1977 Feb;46(2):145-54 [833632.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] J Med Chem. 1980 Jun;23(6):682-4 [7392035.001]
  • [Cites] Cancer Treat Rep. 1980 Feb-Mar;64(2-3):237-44 [7407756.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • (PMID = 17587447.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1919386
  •  go-up   go-down


77. Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E: Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg; 2007 Oct;50(5):273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-seven patients (18 male, 9 female; mean age 42 years; range 11-77 years; 8 low-grade and 11 high-grade astrocytomas or mixed gliomas, 8 oligodendrogliomas) underwent MET PET studies preoperatively.
  • RESULTS: MET PET tumor uptake was detected in 26 of 27 patients (96.3%).
  • The quantitative MET tumor standardized uptake value (SUV) ratio was significantly higher in malignant gliomas and oligodendrogliomas than in low-grade gliomas (2.76/2.62 vs. 1.67, p=0.03).
  • Focal uptake corresponded to malignant glioma histology in 66.7%, and uniform global uptake to oligodendroglial histology in 72.7%.
  • In oligodendrogliomas, global MET uptake constituted 81.5% (range 53.8-135%) of the MRI T(1) tumor volume on average and was limited to the MRI FLAIR tumor volume in 86% (7/8) of patients.
  • CONCLUSION: MET PET image fusion may facilitate the targeting of anaplastic foci in homogeneous MRI non-enhancing gliomas for biopsy, may identify oligodendroglial histology preoperatively as well as characterize biologically active tumor volumes within MRI T(1)/FLAIR tumor areas of candidate patients for resection.
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Radioisotopes. Child. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted / instrumentation. Image Processing, Computer-Assisted / methods. Male. Methionine / metabolism. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / surgery. Predictive Value of Tests. Preoperative Care / instrumentation. Preoperative Care / methods. Sensitivity and Specificity


78. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol; 2009 Apr;174(4):1149-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
  • IDH1 mutations were frequent in low-grade diffuse astrocytomas (88%) and in secondary glioblastomas that developed through progression from low-grade diffuse or anaplastic astrocytoma (82%).
  • Similarly, high frequencies of IDH1 mutations were found in oligodendrogliomas (79%) and oligoastrocytomas (94%).
  • IDH1 mutations were co-present with TP53 mutations in 63% of low-grade diffuse astrocytomas and with loss of heterozygosity 1p/19q in 64% of oligodendrogliomas; they were rare in pilocytic astrocytomas (10%) and primary glioblastomas (5%) and absent in ependymomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / genetics. Female. Humans. Male. Middle Aged. Mutation. Polymorphism, Single-Stranded Conformational. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Hum Genet. 1985;71(1):37-40 [3861566.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • (PMID = 19246647.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ PMC2671348
  •  go-up   go-down


79. Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther; 2007 Jul;6(7):1909-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons learned in the development of targeted therapy for malignant gliomas.
  • The prognosis of patients with glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma remains poor despite standard treatment with radiotherapy and temozolomide.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17620423.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  • [Number-of-references] 78
  •  go-up   go-down


80. Omalu BI, Nnebe-Agumadu UH: Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor. Niger J Clin Pract; 2009 Jun;12(2):200-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor.
  • Chromosome 7q contains putative tumor suppressor genes and is one of the chromosomes that are frequently involved in chromosomal aberrations in human malignancies.
  • We report a case of anaplastic oligodendroglioma that occurred in a 31-year-old man with Williams syndrome.
  • We draw attention to this apparently rare or possibly under-reported occurrence of tumors in patients with Williams syndrome and suggest that Central Nervous System [CNS] tumors be considered as differential diagnoses in such patients when they present with unanticipated neurologic symptoms that are not attributable to those commonly associated with Williams syndrome.
  • [MeSH-major] Brain Neoplasms / epidemiology. Oligodendroglioma / epidemiology. Parietal Lobe. Williams Syndrome / epidemiology


81. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3).
  • Time to tumor progression ranged from 1 to 18 months (median, 6.75 months).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


82. Kocher M, Kunze S, Eich HT, Semrau R, Müller RP: Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol; 2005 Mar;181(3):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
  • PURPOSE: To evaluate the feasibility, safety and efficacy of daily temozolomide concurrent with postoperative radiotherapy in malignant glioma.
  • PATIENTS AND METHODS: From 11/1999 to 03/2003, n = 81 patients aged 15-72 years (median 52 years, Karnofsky score 80-100% in 83%) suffering from primary glioblastoma (n = 47), anaplastic astrocytoma (n = 6), anaplastic oligodendroglioma (n = 16), and recurrent glioma (n = 12) were treated.
  • Grade 1 nausea/vomiting was seen in 28%, grade 2 in 11%, grade 3 in 1%.
  • Hematologic toxicities were observed as follows: leukopenia grade 3/4 1%, lymphopenia grade 3/4 46%, thrombopenia grade 3/4 1%.
  • In oligodendroglioma patients, a 4-year survival rate of 78% was observed.
  • CONCLUSION: Postoperative radiochemotherapy with 30-33 daily doses of temozolomide (75 mg/m(2)) is safe in patients with malignant glioma.
  • The combined schedule is effective in oligodendroglioma patients and may prolong survival in glioblastoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756519.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


83. Siker ML, Chakravarti A, Mehta MP: Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol; 2006 Nov;60(2):99-111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
  • Malignant gliomas are devastating tumors associated with poor prognosis.
  • While it seems intuitive to apply this regimen to patients with anaplastic gliomas which have traditionally been considered more chemosensitive, chemotherapy has not been shown to prolong life in patients with anaplastic gliomas.
  • Despite promising preclinical and early clinical results, there is currently not enough level 1 evidence to justify concomitant and adjuvant temozolomide as standard therapy for patients with newly diagnosed anaplastic gliomas.
  • Further investigation is needed to better define the role of chemotherapy in patients with anaplastic gliomas.
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Combined Modality Therapy. DNA Modification Methylases. DNA Repair Enzymes. Humans. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics. Oligodendroglioma / radiotherapy. Salvage Therapy. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17027279.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 93
  •  go-up   go-down


84. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K: Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol; 2008 Jul;18(3):360-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
  • Intergroup Radiation Therapy Oncology Group Trial 9402 study, a phase III trial of chemotherapy plus radiotherapy (PCV-plus-RT) vs. radiotherapy alone for pure and mixed anaplastic oligodendroglioma confirmed the prognostic significance of 1p 19q deletion and showed that only progression-free survival (PFS) was prolonged in PCV-plus-RT-treated patients and only in association with 1p 19q deletion.
  • We reviewed tumor histopathology, separating 115 tumors deemed to be classic for oligodendroglioma (CFO) from 132 lacking classic features of oligodendroglioma (NCFO) and evaluated the relationship of histopathology and 1p 19q status to treatment and outcome.
  • Median OS for CFO patients with and without necrosis was 6.6 and 6.3 years (OS log-rank P = not significant), respectively, in contrast to NCFO showing 1.9 and 3.3 years respectively (OS log-rank P = 0.014). (ii) Classic oligodendroglial morphology was highly associated with 1p 19q deletion, present in 80% of CFO and only in 13% of NCFO. (iii) On multivariate analysis, both classic oligodendroglial morphology and 1p 19q deletion remained significantly associated with PFS and OS. (iv) Patients with CFO treated with PCV-plus-RT showed a trend toward increased survival compared with CFO treated with RT (P = 0.08).
  • These findings suggest that classic oligodendroglial morphology combined with 1p 19q deletion may in the future be predictive of chemotherapeutic response and survival.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / therapy. Oligodendroglioma / genetics. Oligodendroglioma / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18371182.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


85. Derlon JM, Cabal P, Blaizot X, Borha A, Chapon F: [Metabolic imaging for supratentorial oligodendrogliomas]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):309-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metabolic imaging for supratentorial oligodendrogliomas].
  • Only a few publications have yet reported its use in oligodendroglial tumors.
  • These findings and partial results obtained in ongoing work, suggest some preliminary conclusions: 11C-MET (L-methyl-methionine) is a more appropriate tracer than 18F-FDG (fluoro-deoxy-glucose), in terms of both specificity and sensitivity, for the assessment of patients with this category of tumor.
  • PET/MET allows differentiation between grade II and grade III oligodendrogliomas; better targeting for stereotactic biopsy; more accurate assessment of the post-operative residual tumor; identification of progression from low-grade to anaplastic grade during the disease course; differentiation between recurrence and a post-radiation processes.
  • [MeSH-major] Brain. Oligodendroglioma / metabolism. Positron-Emission Tomography. Supratentorial Neoplasms / metabolism

  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292175.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Radioactive Tracers; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester; IY9XDZ35W2 / Glucose
  •  go-up   go-down


86. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE: A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol; 2008 Sep;89(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
  • BACKGROUND: Anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) are currently treated with a combination of surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy. Radiotherapy, Adjuvant / methods

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):627-42 [8120563.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):156-63 [17541945.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3599-604 [9808553.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 18458821.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


87. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T: Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol; 2006 Sep;79(2):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
  • PURPOSE: Chemotherapy with alkylating agents is of proven efficacy in recurrent anaplastic oligodendroglioma (AO) with reported response rates ranging between 50% and 70%.
  • This study evaluated the response and time to tumor progression of newly diagnosed AO initially treated with TMZ.
  • PATIENTS AND METHODS: Twenty patients with a median age of 47 (range: 26-65) received a median of 14 (range: 3-24) cycles of TMZ as their first modality of therapy following diagnosis of AO.
  • Treatment was given every 28 days for 5 days at a starting dose of 200 mg/m2/d and was continued for 24 cycles unless toxicity or tumor progression required withdrawal of TMZ.
  • The objective response rate was 75%, and median time to tumor progression was 24 months.
  • TMZ was well tolerated with only two events of grade 3/4 hematological toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Pharmacother. 2004 Feb;5(2):295-306 [14996626.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Neurology. 2004 May 25;62(10 ):1783-7 [15159478.001]
  • [Cites] Recent Results Cancer Res. 1994;135:127-33 [8047688.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 16855865.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


88. Trost D, Ehrler M, Fimmers R, Felsberg J, Sabel MC, Kirsch L, Schramm J, Wiestler OD, Reifenberger G, Weber RG: Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. Int J Cancer; 2007 Jun 1;120(11):2368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors.
  • Deletions on chromosomes 1p and 19q are associated with favorable prognosis in patients with oligodendroglial tumors.
  • We performed a genome-wide screen for genomic imbalances by comparative genomic hybridization on tumors from 70 patients, including 40 oligodendrogliomas, 30 oligoastrocytomas (21 WHO grade II tumors, 49 WHO grade III tumors).
  • Multivariate analyses showed the most significant prognostic factors for OS of patients with any oligodendroglial tumor to be WHO grade [odds ratio (OR) 8], 7p gain (OR 6), 9p loss (OR 3); for OS of patients with anaplastic tumors to be 7p gain (OR 10), 8q gain (OR 5), 18q loss (OR 3).
  • Patients with anaplastic oligodendroglial tumors containing one or more prognostically unfavorable genomic aberration had a poor outcome independent of the 1p/19q status.
  • In summary, we identified several independent genomic markers of shorter survival in patients with oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Oligodendroglioma / genetics. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285580.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Gupta M, Djalilvand A, Brat DJ: Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol; 2005 Nov;124(5):755-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
  • Diffuse gliomas are the most common brain tumors and include astrocytomas, oligodendrogliomas, and oligoastrocytomas.
  • Their correct pathologic diagnosis requires the ability to distinguish astrocytic from oligodendroglial differentiation in histologic sections, a challenging feat even for the most experienced neuropathologist.
  • Interobserver variability in the diagnosis of diffuse gliomas has been high owing to subjective diagnostic criteria, overlapping morphologic features, and variations in training and practice among pathologists.
  • A select, albeit imperfect, group of molecular and immunohistochemical tests are available to assist in diagnosis of these lesions.
  • Combined loss of chromosomes 1p and 19q is a genetic signature of oligodendrogliomas, whereas gains of chromosome 7 in the setting of intact 1p/19q are more typical of astrocytomas.
  • Detection of amplified epidermal growth factor receptor favors the diagnosis of high-grade astrocytomas over anaplastic oligodendroglioma, which is especially relevant for small cell astrocytomas.
  • Strong nuclear staining for p53 often reflects TP53 mutation and is typical of low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Genes, p53. Genetic Markers. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Mutation. Receptor, Epidermal Growth Factor / genetics


90. See SJ, Gilbert MR: Chemotherapy in adults with gliomas. Ann Acad Med Singapore; 2007 May;36(5):364-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large clinical studies have provided important information on the impact of chemotherapy for anaplastic oligodendrogliomas in the upfront setting.
  • Investigations are also under way to clarify the role of chemotherapy for low-grade gliomas.
  • This review article summarises the recent developments and approaches in the use of chemotherapy to treat adult patients with astrocytomas and oligodendrogliomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549285.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Singapore
  • [Number-of-references] 37
  •  go-up   go-down


91. Kelly JJ, Blough MD, Stechishin OD, Chan JA, Beauchamp D, Perizzolo M, Demetrick DJ, Steele L, Auer RN, Hader WJ, Westgate M, Parney IF, Jenkins R, Cairncross JG, Weiss S: Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol; 2010 Jul;12(7):745-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma cell lines containing t(1;19)(q10;p10).
  • Investigating the biology of oligodendroglioma and its characteristic combined deletion of chromosomal arms 1p and 19q, mediated by an unbalanced translocation, t(1;19)(q10;p10), has been hampered by the lack of cell lines that harbor these traits.
  • We grew cells from 2 anaplastic oligodendrogliomas in serum-free conditions.
  • Serial propagation and expansion led to the establishment of permanent cell lines that maintained the genetic signature of the parent oligodendrogliomas and displayed features of brain tumor stem cells in vitro.
  • One line was established from a treatment-naïve tumor and the other from a temozolomide resistant recurrent tumor.
  • These lines may be important tools for understanding the biology of oligodendrogliomas and the function of their defining genetic traits.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Cell Line, Tumor. Humans. Translocation, Genetic / genetics


92. Nakamura M, Shimada K, Nakase H, Konishi N: [Clinicopathological diagnosis of gliomas by genotype analysis]. Brain Nerve; 2009 Jul;61(7):773-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological diagnosis of gliomas by genotype analysis].
  • Glioblastomas (WHO grade IV) may develop de novo (primary glioblastomas) or through progression from lower-grade astrocytomas (secondary glioblastomas) both glioblastomas show similar histological features.
  • Oligodendroglioma is recognized as a particular subtype of gliomas that shows remarkable response to chemotherapy [procarbazine+CCNU+vincristine (PCV)], making their correct diagnosis important.
  • However, the histological differentiation of oligodendrogliomas from diffuse astrocytoma could be highly subjective in cases without typical morphological features.
  • Loss of heterozygosity (LOH) on chromosomes 1p and 19q is correlated with sensitivity to PCV chemotherapy with increased survival in anaplastic oligodendroglioma cases (WHO grade III).
  • Similarly, combined LOH on 1p and 19q has been identified as a predictor of favorable overall survival in oligodendrogliomas.
  • We have previously found methylation or expression mosaicism of O6-MGMT in gliomas, resulting in problems on tumor sampling and response to TMZ.
  • This article suggests that more biological and molecular approaches to brain tumor classification will provide improved means to treat these tumors.
  • [MeSH-major] Genotype. Glioblastoma / diagnosis. Glioblastoma / genetics. Molecular Diagnostic Techniques
  • [MeSH-minor] Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Humans. Lomustine / administration & dosage. Loss of Heterozygosity. Pharmacogenetics. Procarbazine / administration & dosage. Prognosis. Tumor Suppressor Proteins / genetics. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618854.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; PCV protocol
  • [Number-of-references] 42
  •  go-up   go-down


93. Palani M, Arunkumar R, Janardhanam VA: Biochemical and cytogenetic analysis of brain tissues in different grades of glioma patients. Ann Neurosci; 2010 Jul;17(3):120-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glioma, a neoplasm of neuroglial cells, is the most common type of brain tumor, constituting more than 50% of all brain tumors.
  • METHODS: Sixty patients with different grades of glioma include glioblastoma multiforme (n=20), Anaplastic astrocytoma (n=10).
  • Oligodendroglioma (n=10).
  • CK, Na-K(+) ATPases, 5'-Nucleotidases showed marked increase in grade IV.
  • Similarly, Mg2-ATPase, Ca2+ATPases showed significant increase in grade III.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25205887.001).
  • [ISSN] 0972-7531
  • [Journal-full-title] Annals of neurosciences
  • [ISO-abbreviation] Ann Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4116979
  • [Keywords] NOTNLM ; Antioxidants / Biochemical profile in glioma / Chromosomal aberrations / Enzymes / Glioma
  •  go-up   go-down


94. Higgins RJ, Dickinson PJ, LeCouteur RA, Bollen AW, Wang H, Wang H, Corely LJ, Moore LM, Zang W, Fuller GN: Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. J Neurooncol; 2010 May;98(1):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-seven spontaneous canine gliomas were histologically classified and graded using the latest World Health Organization (WHO 2007) criteria for classification of human gliomas.
  • A total of 19 canine astrocytomas were classified as follows: grade IV (GBM) n = 7; grade III n = 5; and grade II, n = 7.
  • Thirty-eight oligodendrogliomas were classified as either grade III (anaplastic) n = 35 or low grade II n = 3.
  • Tissue microarray (TMA) immunohistochemistry was used to evaluate tumor expression of EGFR, PDGFRa and IGFBP2, three key molecules of known pathophysiological importance in human gliomas.
  • Findings were correlated with tumor classification and grade.
  • Increased EGFR expression was demonstrated in 57% of GBMs, 40% of grade III and 28% of grade II astrocytomas.
  • EGFR expression occurred in only 3% of grade III oligodendrogliomas.
  • Increased expression of PDGFRalpha was demonstrated in 43% of GBMs, 20% of grade III, and 14% of grade II astrocytomas.
  • In the oligodendroglioma series, 94% of grade III tumors overexpressed PDGFRalpha.
  • IGFBP2 expression was detected in 71, 60 and 28% of GBMs, grade III and grade II astrocytomas respectively.
  • IGFBP2 expression occurred in 48% of anaplastic and in 33% of low grade oligodendrogliomas.
  • Expression of EGFR, PDGFRalpha or IGFBP2 was not detected in normal canine CNS control TMA cores.
  • The incidence of overexpression of EGFR, PDGFRalpha and IGFBP2 in these canine gliomas closely parallels that in human tumors of similar type and grade.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1996 Jul;149(1):29-35 [8686753.001]
  • [Cites] Endocrinology. 2001 Apr;142(4):1652-8 [11250947.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14085-91 [16569642.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):95-107 [11770905.001]
  • [Cites] Vet Pathol. 2004 Jan;41(1):10-9 [14715963.001]
  • [Cites] J Neurooncol. 2008 May;88(1):11-7 [18246408.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 May;66(5):405-17 [17483698.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):864-73; discussion 873-4 [11322447.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Vet Pathol. 2003 Nov;40(6):659-69 [14608019.001]
  • [Cites] J Histochem Cytochem. 2000 Aug;48(8):1103-10 [10898803.001]
  • [Cites] J Natl Cancer Inst. 1971 Dec;47(6):1333-44 [5120412.001]
  • [Cites] Vet Comp Oncol. 2006 Sep;4(3):132-40 [19754810.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4783-9 [15256447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11736-41 [17606927.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):87-94 [11770904.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503 [10850862.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):397-406 [15967117.001]
  • (PMID = 19967449.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


95. Belda-Iniesta C, de Castro Carpeño J, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M: Molecular biology of malignant gliomas. Clin Transl Oncol; 2006 Sep;8(9):635-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology of malignant gliomas.
  • For example, gliomas of astrocytic origin (astrocytomas) are classified into pilocytic astrocytoma (grade I), astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme (GMB) (grade IV).
  • Tumors derived from oligodendrocytes include grade II (oliogodendrogliomas) and grade III neoplasms (oligoastrocytoma).
  • In this regard, a patient diagnosed with an oligodendroglioma totally removed has 10-15 years of potential survival.
  • On the opposite site, patients carrying a glioblastoma multiforme usually die within the first year after the diagnosis is made.
  • Obviously, prognosis and biological behaviour of malignant gliomas are closely related and supported by the different molecular background that possesses each type of glioma.
  • Furthermore, the ability that allows several low-grade gliomas to progress into more aggressive tumors has allowed cancer researchers to elucidate several pathways implicated in molecular biology of these devastating tumors.
  • In this review, we describe classical pathways involved in human malignant gliomas with special focus with recent advances, such as glioma stem-like cells and expression patterns from microarray studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cell. 1995 Dec 15;83(6):993-1000 [8521522.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4088-96 [15899798.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]
  • [Cites] Cell Cycle. 2006 Apr;5(7):783-91 [16582634.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):193-204 [15023437.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):386-92 [7635563.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):311-6 [12726857.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Physiol Genomics. 2001 Feb 07;5(1):21-33 [11161003.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4051-8 [15899794.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4183-6 [9331071.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Feb;57(2):122-30 [9600204.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3644-9 [9851971.001]
  • [Cites] Cell. 2004 Apr 16;117(2):211-23 [15084259.001]
  • [Cites] J Neurooncol. 1998 Jan;36(2):123-40 [9525812.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1941-5 [7728764.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5804-7 [7954404.001]
  • [Cites] Oncogene. 2004 Jun 3;23 (26):4594-602 [15077177.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Oct;11(2):91-6 [7529554.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]
  • (PMID = 17005465.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 36
  •  go-up   go-down


96. Wager M, Menei P, Guilhot J, Levillain P, Michalak S, Bataille B, Blanc JL, Lapierre F, Rigoard P, Milin S, Duthe F, Bonneau D, Larsen CJ, Karayan-Tapon L: Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study. Br J Cancer; 2008 Jun 3;98(11):1830-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Univariate analysis was followed by multivariate analysis according to a Cox model. p14(ARF), p16(INK4A) and PTEN expressions, and 10p 10q23, 10q26 and 13q LOH for the entire cohort, hTERT expression for high-grade tumours, EGFR for glioblastomas, 10q26 LOH for grade III tumours and anaplastic oligodendrogliomas were found to be correlated with overall survival on univariate analysis and age and grade on multivariate analysis only.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Decision Making. Humans. Loss of Heterozygosity. Middle Aged. Multivariate Analysis. Prognosis. Promoter Regions, Genetic. Prospective Studies. Telomerase / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2006 Jun;28(6):1555-60 [16685456.001]
  • [Cites] Cancer Lett. 2006 Feb 8;232(2):139-47 [16139423.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4412-7 [16983109.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1062-9 [17047653.001]
  • [Cites] Cell Prolif. 2007 Feb;40(1):14-23 [17227292.001]
  • [Cites] Brain Res. 2007 Feb 23;1134(1):45-52 [17196947.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1470-5 [17442989.001]
  • [Cites] Brain Pathol. 2007 Jan;17(1):5-10 [17493032.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):13-24 [17520692.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):733-6 [17882276.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8980-4 [17908997.001]
  • [Cites] J Surg Oncol. 2004 Apr 1;86(1):34-40 [15048678.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2387-95 [11489817.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):169-76 [11550311.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jan;126(1):42-8 [11800646.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):592-8 [11849778.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1790-6 [11912156.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Clin Neuropathol. 2002 Mar-Apr;21(2):52-65 [12005253.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):516-20 [12592364.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4884-90 [14581362.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Int J Oncol. 2003 Dec;23(6):1529-35 [14612923.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):10-20 [17319279.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):141-50 [17115285.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1459-60 [17442986.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4933-8 [15297393.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):789-95 [15375501.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] J Korean Med Sci. 1995 Dec;10(6):442-8 [8924230.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Oncogene. 1998 Apr 30;16(17):2259-64 [9619835.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):387-94 [10433932.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):581-7 [15455376.001]
  • [Cites] Surg Neurol. 2005 Feb;63(2):162-9; discussion 169 [15680662.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1462-6 [15746047.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):802-10 [15792519.001]
  • [Cites] Arch Pathol Lab Med. 2005 May;129(5):624-31 [15859633.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Drug Resist Updat. 2005 Feb-Apr;8(1-2):75-83 [15939344.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5294-304 [15998902.001]
  • [Cites] Clin Neuropathol. 2005 Sep-Oct;24(5):209-18 [16167544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):695-703 [15936158.001]
  • [Cites] Surg Neurol. 2005 Oct;64(4):286-94; discussion 294 [16229087.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E23 [16709029.001]
  • (PMID = 18506188.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2410116
  •  go-up   go-down


97. Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, Kang JK, Kim MC, Hong YK: Temozolomide chemotherapy in patients with recurrent malignant gliomas. J Korean Med Sci; 2006 Aug;21(4):739-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide chemotherapy in patients with recurrent malignant gliomas.
  • Numerous studies have demonstrated the clinical activity of temozolomide, a second-generation alkylating agent, against malignant brain tumors, however, its activity has not been reported in an Asian population.
  • This study analyzed the efficacy and toxicity of temozolomide in 25 adult patients with recurrent or progressive malignant gliomas after surgery and standard radiation therapy with or without chemotherapy, enrolled in our institution since July 2000.
  • Sixteen patients had glioblastoma multiforme (GBM), six with anaplastic astrocytoma, and three with anaplastic oligodendroglioma.
  • Temozolomide demonstrated moderate activity in recurrent and progressive malignant gliomas without serious toxicity.
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Brain / drug effects. Brain / pathology. Combined Modality Therapy. Drug Administration Schedule. Drug-Induced Liver Injury. Female. Humans. Leukopenia / chemically induced. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Survival Analysis. Treatment Outcome. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):325-7 [11437571.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1383-8 [11870183.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Cancer Treat Rev. 2002 Apr;28(2):115-20 [12297119.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):255-7 [11300334.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Eur J Cancer. 1993;29A(7):940-2 [8499146.001]
  • [Cites] J Clin Epidemiol. 1997 Apr;50(4):441-50 [9179103.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):263-78 [9258818.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(6):484-8 [9332462.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):501-5 [11870527.001]
  • (PMID = 16891823.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2729901
  •  go-up   go-down


98. Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M, Iwata R, Higano S, Takanami K, Takai Y, Tominaga T: Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg; 2010 Aug;113(2):358-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Assessment of hypoxic conditions in brain tumors is important for predicting tumor aggressiveness and treatment response.
  • METHODS: The FRP-170 was injected and PET imaging was performed 2 hours later in 8 patients, including 3 with glioblastoma multiforme, 2 with oligodendroglioma, and 1 each with diffuse astrocytoma, anaplastic ganglioglioma, and recurrent anaplastic astrocytoma.
  • Tissues obtained at biopsy or radical resection were immunostained with hypoxia-inducible factor-1alpha (HIF-1alpha) antibody for the confirmation of hypoxia, except in the patient with recurrent anaplastic astrocytoma who was treated using Gamma Knife surgery.
  • RESULTS: The FRP-170 PET images showed marked uptake with upregulation of HIF-1alpha in the 3 glioblastomas multiforme, and moderate uptake in the recurrent anaplastic astrocytoma and one oligodendroglioma, but no uptake in the other tumors.
  • This new method can assess tumor hypoxia preoperatively and noninvasively.
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Biopsy. Carbon Isotopes. Cell Division. Female. Fluorodeoxyglucose F18. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Methionine. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Protons. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895196.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / FRP-170; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nitroimidazoles; 0 / Protons; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


99. Adamek D, Dec M, Sobol G, Urbanowicz B, Jaworski M: Giant cell ependymoma: a case report. Clin Neurol Neurosurg; 2008 Feb;110(2):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological, immunohistochemical and electron microscopic findings were consistent with high-grade ependymoma.
  • Especially striking was the presence of bizzare pleomorphic giant cells which predominated in the tumor tissue.
  • As a result the diagnosis of GCE was established.
  • This type of neoplasm necessitates, at least in theory, differentiation with anaplastic oligodendroglioma, clear cell ependymoma, pleomorphic xanthoastrocytoma, giant cell glioblastoma, and subependymal giant cell astrocytoma.
  • In spite of apparently "worrisome" histology GCE seems to be a neoplasm with a relatively good prognosis.

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006220.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


100. Kasliwal MK, Agrawal D, Mahapatra AK: MR Imaging in anaplastic oligodendroglioma. J Neurooncol; 2005 Aug;74(1):97-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR Imaging in anaplastic oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Oligodendroglioma / diagnostic imaging






Advertisement